DE10122342A1 - Use of isoflavones in cosmetic or dermatological preparations - Google Patents
Use of isoflavones in cosmetic or dermatological preparationsInfo
- Publication number
- DE10122342A1 DE10122342A1 DE2001122342 DE10122342A DE10122342A1 DE 10122342 A1 DE10122342 A1 DE 10122342A1 DE 2001122342 DE2001122342 DE 2001122342 DE 10122342 A DE10122342 A DE 10122342A DE 10122342 A1 DE10122342 A1 DE 10122342A1
- Authority
- DE
- Germany
- Prior art keywords
- skin
- isoflavone
- hydroxy
- cosmetic
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 41
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims description 9
- 235000008696 isoflavones Nutrition 0.000 title claims description 9
- 150000002515 isoflavone derivatives Chemical class 0.000 title claims description 5
- 239000000126 substance Substances 0.000 claims abstract description 37
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 238000011321 prophylaxis Methods 0.000 claims abstract description 11
- ZZUBHVMHNVYXRR-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2h-chromen-7-ol Chemical compound C1=CC(O)=CC=C1C1=CC2=CC=C(O)C=C2OC1 ZZUBHVMHNVYXRR-UHFFFAOYSA-N 0.000 claims abstract description 8
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960005431 ipriflavone Drugs 0.000 claims abstract description 8
- 208000003251 Pruritus Diseases 0.000 claims abstract description 6
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 claims abstract description 5
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- MPNKZWIUITZJCR-UHFFFAOYSA-N 2-Dehydro-O-desmethylangolensin Chemical compound C1=CC(O)=CC=C1C(=C)C(=O)C1=CC=C(O)C=C1O MPNKZWIUITZJCR-UHFFFAOYSA-N 0.000 claims abstract description 4
- BPPHVEDGYFQWJV-UHFFFAOYSA-N 2-hydroxy-3-phenyl-2,3,4a,5-tetrahydrochromen-4-one Chemical compound OC1OC2=CC=CCC2C(=O)C1C1=CC=CC=C1 BPPHVEDGYFQWJV-UHFFFAOYSA-N 0.000 claims abstract description 4
- CPBYTAYFHIHDNI-UHFFFAOYSA-N 2-hydroxy-3-phenyl-2,3-dihydrochromen-4-one Chemical compound OC1OC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 CPBYTAYFHIHDNI-UHFFFAOYSA-N 0.000 claims abstract description 4
- AEWGNLRDPNOCSH-UHFFFAOYSA-N 3-(4-propan-2-ylphenyl)chromen-4-one Chemical compound C1=CC(C(C)C)=CC=C1C1=COC2=CC=CC=C2C1=O AEWGNLRDPNOCSH-UHFFFAOYSA-N 0.000 claims abstract description 4
- JHYXBPPMXZIHKG-CYBMUJFWSA-N Dihydrodaidzein Natural products C1=CC(O)=CC=C1[C@@H]1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-CYBMUJFWSA-N 0.000 claims abstract description 4
- JDJPNKPFDDUBFV-UHFFFAOYSA-N O-Desmethylangolensin Chemical compound C=1C=C(O)C=CC=1C(C)C(=O)C1=CC=C(O)C=C1O JDJPNKPFDDUBFV-UHFFFAOYSA-N 0.000 claims abstract description 4
- DPCMZUHKNHLUKT-UHFFFAOYSA-N OC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 Chemical compound OC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 DPCMZUHKNHLUKT-UHFFFAOYSA-N 0.000 claims abstract description 4
- JHYXBPPMXZIHKG-UHFFFAOYSA-N dihydrodaidzein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-UHFFFAOYSA-N 0.000 claims abstract description 4
- UQGVUYNHDKMLSE-UHFFFAOYSA-N dihydrogenistein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=C(O)C=C(O)C=C2OC1 UQGVUYNHDKMLSE-UHFFFAOYSA-N 0.000 claims abstract description 4
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims abstract description 4
- LEPIDOXLUUYARR-UHFFFAOYSA-N formononetin-7-O-beta-D-glucopyranoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=C(O)C=C2C1=O LEPIDOXLUUYARR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- 210000003491 skin Anatomy 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 230000036074 healthy skin Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- YVLPJIGOMTXXLP-UHFFFAOYSA-N 15-cis-phytoene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CC=CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C YVLPJIGOMTXXLP-UHFFFAOYSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- 206010011953 Decreased activity Diseases 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 229940000033 dermatological agent Drugs 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 230000005778 DNA damage Effects 0.000 claims description 3
- 231100000277 DNA damage Toxicity 0.000 claims description 3
- 230000006820 DNA synthesis Effects 0.000 claims description 3
- INYISIYHXQDCPK-CQSZACIVSA-N Dihydroformononetin Natural products C1=CC(OC)=CC=C1[C@@H]1C(=O)C2=CC=C(O)C=C2OC1 INYISIYHXQDCPK-CQSZACIVSA-N 0.000 claims description 3
- 206010051246 Photodermatosis Diseases 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 208000017983 photosensitivity disease Diseases 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000037307 sensitive skin Effects 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 2
- YVLPJIGOMTXXLP-UUKUAVTLSA-N 15,15'-cis-Phytoene Natural products C(=C\C=C/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C YVLPJIGOMTXXLP-UUKUAVTLSA-N 0.000 claims description 2
- YVLPJIGOMTXXLP-BAHRDPFUSA-N 15Z-phytoene Natural products CC(=CCCC(=CCCC(=CCCC(=CC=C/C=C(C)/CCC=C(/C)CCC=C(/C)CCC=C(C)C)C)C)C)C YVLPJIGOMTXXLP-BAHRDPFUSA-N 0.000 claims description 2
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 235000000638 D-biotin Nutrition 0.000 claims description 2
- 239000011665 D-biotin Substances 0.000 claims description 2
- 230000008265 DNA repair mechanism Effects 0.000 claims description 2
- 208000001840 Dandruff Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241000219793 Trifolium Species 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 230000008568 cell cell communication Effects 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- 210000002808 connective tissue Anatomy 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000037149 energy metabolism Effects 0.000 claims description 2
- 230000013632 homeostatic process Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims description 2
- 230000037356 lipid metabolism Effects 0.000 claims description 2
- 230000003859 lipid peroxidation Effects 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 230000000065 osmolyte Effects 0.000 claims description 2
- 235000011765 phytoene Nutrition 0.000 claims description 2
- 230000004481 post-translational protein modification Effects 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 2
- 230000037067 skin hydration Effects 0.000 claims description 2
- 230000000391 smoking effect Effects 0.000 claims description 2
- 230000036572 transepidermal water loss Effects 0.000 claims description 2
- 240000007124 Brassica oleracea Species 0.000 claims 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- UVLLPEUWLRYAFL-UHFFFAOYSA-N 7-hydroxy-3-(4-hydroxyphenyl)-2,3,4a,5-tetrahydrochromen-4-one Chemical compound C1OC2=CC(O)=CCC2C(=O)C1C1=CC=C(O)C=C1 UVLLPEUWLRYAFL-UHFFFAOYSA-N 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 abstract 1
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- -1 hydroxy radicals Chemical class 0.000 description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000001993 wax Substances 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000004904 UV filter Substances 0.000 description 8
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 229920002545 silicone oil Polymers 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000001023 inorganic pigment Substances 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229930013032 isoflavonoid Natural products 0.000 description 4
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 4
- 235000012891 isoflavonoids Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 235000010215 titanium dioxide Nutrition 0.000 description 4
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 3
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 3
- IYAZLDLPUNDVAG-UHFFFAOYSA-N 2-(benzotriazol-2-yl)-4-(2,4,4-trimethylpentan-2-yl)phenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(N2N=C3C=CC=CC3=N2)=C1 IYAZLDLPUNDVAG-UHFFFAOYSA-N 0.000 description 3
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940086555 cyclomethicone Drugs 0.000 description 3
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000006552 photochemical reaction Methods 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- WAYINTBTZWQNSN-UHFFFAOYSA-N 11-methyldodecyl 3,5,5-trimethylhexanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CC(C)CC(C)(C)C WAYINTBTZWQNSN-UHFFFAOYSA-N 0.000 description 2
- SKMJTOFLXWKGKH-UHFFFAOYSA-N 11-methyldodecyl 7-methyloctanoate Chemical compound CC(C)CCCCCCCCCCOC(=O)CCCCCC(C)C SKMJTOFLXWKGKH-UHFFFAOYSA-N 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- NPSJHQMIVNJLNN-UHFFFAOYSA-N 2-ethylhexyl 4-nitrobenzoate Chemical compound CCCCC(CC)COC(=O)C1=CC=C([N+]([O-])=O)C=C1 NPSJHQMIVNJLNN-UHFFFAOYSA-N 0.000 description 2
- 239000004808 2-ethylhexylester Substances 0.000 description 2
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- DQNLRFRBAWCJHQ-UHFFFAOYSA-N 5-hydroxy-7-methoxy-3-(4-methoxyphenyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(OC)=CC(O)=C2C1=O DQNLRFRBAWCJHQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- 230000037338 UVA radiation Effects 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical group 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930016911 cinnamic acid Natural products 0.000 description 2
- 235000013985 cinnamic acid Nutrition 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical compound C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 229940037395 electrolytes Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 229940074928 isopropyl myristate Drugs 0.000 description 2
- 229940089456 isopropyl stearate Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004611 light stabiliser Substances 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- QAOJADINKLMTRR-UHFFFAOYSA-N octan-3-yl 16-methylheptadecanoate Chemical compound CCCCCC(CC)OC(=O)CCCCCCCCCCCCCCC(C)C QAOJADINKLMTRR-UHFFFAOYSA-N 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- QYXHQRJWUMDWGJ-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methylidene]propanedioic acid Chemical compound COC1=CC=C(C=C(C(O)=O)C(O)=O)C=C1 QYXHQRJWUMDWGJ-UHFFFAOYSA-N 0.000 description 1
- KXTAOXNYQGASTA-UHFFFAOYSA-N 2-benzylidenepropanedioic acid Chemical compound OC(=O)C(C(O)=O)=CC1=CC=CC=C1 KXTAOXNYQGASTA-UHFFFAOYSA-N 0.000 description 1
- QSNJNCHUFWULBZ-UHFFFAOYSA-N 2-ethylhexyl 16-methylheptadecanoate Chemical compound CCCCC(CC)COC(=O)CCCCCCCCCCCCCCC(C)C QSNJNCHUFWULBZ-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- LWLRMRFJCCMNML-UHFFFAOYSA-N 2-ethylhexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CC)CCCC LWLRMRFJCCMNML-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- MWKPHOIHTLQZIY-UHFFFAOYSA-N 2-hexyldecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC MWKPHOIHTLQZIY-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- RUDXBXPTJPNTSO-UHFFFAOYSA-N 2-octyldodecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC RUDXBXPTJPNTSO-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical class OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- NGJJZCPADSICRI-UHFFFAOYSA-N 4-[[4,6-bis(4-carboxyanilino)-1,3,5-triazin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N=C(NC(=NC=1C=CC(=CC=1)C(O)=O)N1)NC1=NC1=CC=C(C(O)=O)C=C1 NGJJZCPADSICRI-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
- 150000005418 4-aminobenzoic acid derivatives Chemical class 0.000 description 1
- SJIDAAGFCNIAJP-UHFFFAOYSA-N 6-methylheptyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCC(C)C SJIDAAGFCNIAJP-UHFFFAOYSA-N 0.000 description 1
- XUVVLJKRLAXOKZ-UHFFFAOYSA-N 7-methyloctyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCC(C)C XUVVLJKRLAXOKZ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- BZUVPTAFNJMPEZ-CLFAGFIQSA-N [(z)-docos-13-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCOC(=O)CCCCCCCCCCC\C=C/CCCCCCCC BZUVPTAFNJMPEZ-CLFAGFIQSA-N 0.000 description 1
- TXZRBCSUYLEATA-GALHSAGASA-N [(z)-docos-13-enyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC TXZRBCSUYLEATA-GALHSAGASA-N 0.000 description 1
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 description 1
- RLZLDSDDRORMOV-DBQHITQZSA-M [Na+].Cl.COc1ccc2cc(ccc2c1)[C@H](C)C([O-])=O.CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC Chemical compound [Na+].Cl.COc1ccc2cc(ccc2c1)[C@H](C)C([O-])=O.CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC RLZLDSDDRORMOV-DBQHITQZSA-M 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229940071097 ascorbyl phosphate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 150000001565 benzotriazoles Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960003055 bisoctrizole Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000012185 ceresin wax Substances 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical class N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 231100001144 environmental noxa Toxicity 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- HTDJPCNNEPUOOQ-UHFFFAOYSA-N hexamethylcyclotrisiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O1 HTDJPCNNEPUOOQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229940078546 isoeicosane Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000020130 leben Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- MJVGBKJNTFCUJM-UHFFFAOYSA-N mexenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=C(C)C=C1 MJVGBKJNTFCUJM-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- AXIUTKTZNZMMSI-UHFFFAOYSA-N octan-3-yl 2-cyano-3,3-diphenylprop-2-enoate Chemical compound C=1C=CC=CC=1C(=C(C#N)C(=O)OC(CC)CCCCC)C1=CC=CC=C1 AXIUTKTZNZMMSI-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- RAFYDKXYXRZODZ-UHFFFAOYSA-N octanoyl octanoate Chemical compound CCCCCCCC(=O)OC(=O)CCCCCCC RAFYDKXYXRZODZ-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940120511 oleyl erucate Drugs 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- LXTZRIBXKVRLOA-UHFFFAOYSA-N padimate a Chemical compound CCCCCOC(=O)C1=CC=C(N(C)C)C=C1 LXTZRIBXKVRLOA-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229920003216 poly(methylphenylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- PZQSQRCNMZGWFT-QXMHVHEDSA-N propan-2-yl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC(C)C PZQSQRCNMZGWFT-QXMHVHEDSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 239000010420 shell particle Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft die Verwendung spezieller Isoflavonoide in kosmeti schen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut, Juckreiz sowie von Veränderungen der DNS-Synthese- und/oder DNS- Reparaturleistung in der Haut.The present invention relates to the use of specific isoflavonoids in kosmeti or dermatological preparations for the prophylaxis and treatment of sensitive skin, itching and changes in DNA synthesis and / or DNA Repair performance in the skin.
Insbesondere betrifft die vorliegende Erfindung kosmetische Zubereitungen mit einem zusätzlichen, wirksamen Schutz vor schädlichen Oxidationsprozessen in der Haut, aber auch zum zusätzlichen Schutz kosmetischer Zubereitungen selbst bzw. zum zusätzli chen Schutz der Bestandteile kosmetischer Zubereitungen vor schädlichen Oxidations prozessen.In particular, the present invention relates to cosmetic preparations with a additional, effective protection against harmful oxidation processes in the skin, however also for additional protection of cosmetic preparations themselves or to addi protection of the constituents of cosmetic preparations against harmful oxidation processes.
Unter kosmetischer Hautpflege ist in erster Linie zu verstehen, daß die natürliche Funk tion der Haut als Barriere gegen Umwelteinflüsse (z. B. Schmutz, Chemikalien, Mikroor ganismen) und gegen den Verlust von körpereigenen Stoffen (z. B. Wasser, natürliche Fette, Elektrolyte) gestärkt oder wiederhergestellt wird.Under cosmetic skincare is to be understood in the first place that the natural radio the skin as a barrier against environmental influences (eg dirt, chemicals, microorgan organisms) and against the loss of endogenous substances (eg water, natural Fats, electrolytes) is strengthened or restored.
Wird diese Funktion gestört, kann es zu verstärkter Resorption toxischer oder allergener Stoffe oder zum Befall von Mikroorganismen und als Folge zu toxischen oder allergi schen Hautreaktionen kommen.If this function is disturbed, it can lead to increased absorption of toxic or allergenic Substances or infestation of microorganisms and as a result to toxic or allergi skin reactions.
Ziel der Hautpflege ist es ferner, den durch tägliche Waschen verursachten Fett- und Wasserverlust der Haut auszugleichen. Dies ist gerade dann wichtig, wenn das natürli che Regenerationsvermögen nicht ausreicht. Außerdem sollen Hautpflegeprodukte vor Umwelteinflüssen, insbesondere vor Sonne und Wind, schützen und die Hautalterung verzögern.It is also the goal of skin care to reduce the fat and thinning caused by daily washing To compensate for water loss of the skin. This is important when the natural regenerative capacity is insufficient. In addition, skin care products are intended Environmental influences, especially against sun and wind, protect and skin aging delay.
Die chronologische Hautalterung wird z. B. durch endogene, genetisch determinierte
Faktoren verursacht. In Epidermis und Dermis kommt es alterungsbedingt z. B. zu fol
genden Strukturschäden und Funktionsstörungen, die auch unter den Begriff "Senile
Xerosis" fallen können:
The chronological skin aging is z. B. caused by endogenous, genetically determined factors. In epidermis and dermis it comes due to aging z. B. to fol lowing structural damage and dysfunction, which may also fall under the term "senile xerosis":
- a) Trockenheit, Rauhigkeit und Ausbildung von Trockenheitsfältchen,a) dryness, roughness and formation of dryness wrinkles,
- b) Juckreiz undb) itching and
- c) verminderte Rückfettung durch Talgdrüsen (z. B. nach Waschen).c) diminished fatty acid regeneration (eg after washing).
Exogene Faktoren, wie UV-Licht und chemische Noxen, können kumulativ wirksam sein.
In Epidermis und Dermis kommt es insbesondere durch exogene Faktoren z. B. zu fol
genden Strukturschäden- und Funktionsstörungen in der Haut:
Exogenous factors such as UV light and chemical noxae can be cumulatively effective. In epidermis and dermis it comes in particular by exogenous factors z. B. to fol lowing structural damage and dysfunction in the skin:
- a) vergrößerte Anfälligkeit gegenüber mechanischem Stress (z. B. Rissigkeit).a) increased susceptibility to mechanical stress (eg cracking).
Produkte zur Pflege sensibler, juckender und/oder trockener Haut bzw. Produkte zur Behandlung von oder Prophylaxe vor DNS-Schädigungen sind an sich bekannt. Aller dings ist deren Wirksamkeit begrenzt.Products for the care of sensitive, itchy and / or dry skin or products Treatment or prophylaxis of DNA damage is known per se. all However, their effectiveness is limited.
Die schädigende Wirkung des ultravioletten Teils der Sonnenstrahlung auf die Haut ist allgemein bekannt. Während Strahlen mit einer Wellenlänge, die kleiner als 290 nm ist (der sogenannte UVC-Bereich), von der Ozonschicht in der Erdatmosphäre absorbiert werden, verursachen Strahlen im Bereich zwischen 290 nm und 320 nm, dem soge nannten UVB-Bereich, ein Erythem, einen einfachen Sonnenbrand oder sogar mehr oder weniger starke Verbrennungen.The damaging effect of the ultraviolet part of solar radiation on the skin is well known. While rays with a wavelength smaller than 290 nm (the so-called UVC range), absorbed by the ozone layer in the earth's atmosphere be, cause rays in the range between 290 nm and 320 nm, the soge called UVB, erythema, simple sunburn or even more or less severe burns.
Als ein Maximum der Erythemwirksamkeit des Sonnenlichtes wird der engere Bereich um 308 nm angegeben.As a maximum of the erythema efficiency of sunlight becomes the narrower area indicated at 308 nm.
Zum Schutz gegen UVB-Strahlung sind zahlreiche Verbindungen bekannt, bei denen es sich um Derivate des 3-Benzylidencamphers, der 4-Aminobenzoesäure, der Zimtsäure, der Salicylsäure, des Benzophenons sowie auch des 2-Phenylbenzimidazols handelt.For protection against UVB radiation, numerous compounds are known in which it derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and 2-phenylbenzimidazole.
Auch für den Bereich zwischen etwa 320 nm und etwa 400 nm, des sogenannten UVA- Bereich, ist es wichtig, Filtersubstanzen zur Verfügung zu haben, da dessen Strahlen Reaktionen bei lichtempfindlicher Haut hervorrufen können. Es ist erwiesen, daß UVA- Strahlung zu einer Schädigung der elastischen und kollagenen Fasern des Bindegewe bes führt, was die Haut vorzeitig altern läßt, und daß sie als Ursache zahlreicher photo toxischer und photoallergischer Reaktionen zu sehen ist. Der schädigende Einfluß der UVB-Strahlung kann durch UVA-Strahlung verstärkt werden.Also for the range between about 320 nm and about 400 nm, the so-called UVA Area, it is important to have filter substances available as its rays Can cause reactions in photosensitive skin. It has been proven that UVA Radiation damage the elastic and collagen fibers of the connective tissue What leads the skin to prematurely age, and that it is the cause of numerous photo toxic and photoallergic reactions can be seen. The damaging influence of UVB radiation can be amplified by UVA radiation.
Zum Schutz gegen die Strahlen des UVA-Bereichs werden daher gewisse Derivate des Dibenzoylmethans verwendet, deren Photostabilität (Int. J. Cosm. Science 10, 53 (1988)), nicht in ausreichendem Maße gegeben ist.For protection against the rays of the UVA range, therefore, certain derivatives of the Dibenzoylmethane, whose photostability (Int J. Cosm. Science 10, 53 (1988)), is not given sufficiently.
Die UV-Strahlung kann aber auch zu photochemischen Reaktionen führen, wobei dann die photochemischen Reaktionsprodukte in den Hautmetabolismus eingreifen.The UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin metabolism.
Vorwiegend handelt es sich bei solchen photochemischen Reaktionsprodukten um ra dikalische Verbindungen, beispielsweise Hydroxyradikale. Auch undefinierte radikali sche Photoprodukte, welche in der Haut selbst entstehen, können aufgrund ihrer hohen Reaktivität unkontrollierte Folgereaktionen an den Tag legen. Aber auch Singulettsauer stoff, ein nichtradikalischer angeregter Zustand des Sauerstoffmoleküls kann bei UV- Bestrahlung auftreten, ebenso kurzlebige Epoxide und viele andere. Singulettsauerstoff beispielsweise zeichnet sich gegenüber dem normalerweise vorliegenden Triplettsau erstoff (radikalischer Grundzustand) durch gesteigerte Reaktivität aus. Allerdings existie ren auch angeregte, reaktive (radikalische) Triplettzustände des Sauerstoffmoleküls.Predominantly, such photochemical reaction products are ra dicalic compounds, for example hydroxy radicals. Also undefined radical Photoproducts, which develop in the skin itself, can due to their high Reactivity uncontrolled subsequent reactions to the day. But also Singulettsauer substance, a non-radical excited state of the oxygen molecule can be Irradiation occur, as are short-lived epoxides and many others. singlet For example, is distinguished from the normally existing Triplettsau erstoff (radical ground state) by increased reactivity. However, there exists also excited, reactive (radical) triplet states of the oxygen molecule.
Ferner zählt UV-Strahlung zur ionisierenden Strahlung. Es besteht also das Risiko, daß auch ionische Spezies bei UV-Exposition entstehen, welche dann ihrerseits oxidativ in die biochemischen Prozesse einzugreifen vermögen.Furthermore, UV radiation counts as ionizing radiation. So there is a risk that also arise ionic species on UV exposure, which in turn oxidative in to be able to intervene in the biochemical processes.
Um diesen Reaktionen vorzubeugen, können den kosmetischen bzw. dermatologischen Formulierungen zusätzliche Antioxidantien und/oder Radikalfänger einverleibt werden. To prevent these reactions, the cosmetic or dermatological Formulations additional antioxidants and / or radical scavengers are incorporated.
Es ist bereits vorgeschlagen worden, Vitamin E, eine Substanz mit bekannter antioxida tiver Wirkung in Lichtschutzformulierungen einzusetzen, dennoch bleibt auch hier die erzielte Wirkung weit hinter der erhofften zurück.It has already been suggested vitamin E, a substance with known antioxida tive effect in sunscreen formulations, but still remains here scored far behind the hoped for effect.
Aufgabe der Erfindung war es daher, kosmetische, dermatologische und pharmazeuti sche Wirkstoffe und Zubereitungen sowie Lichtschutzformulierungen zu schaffen, die zur Prophylaxe und Behandlung lichtempfindlicher Haut, insbesondere von Photoder matosen, bevorzugt der polymorphen Lichtdermatose dienen.The object of the invention was, therefore, cosmetic, dermatological and pharmi to provide active substances and preparations as well as sunscreen formulations which for the prophylaxis and treatment of photosensitive skin, especially photoderms matose, preferably the polymorphic light dermatosis serve.
Weitere Bezeichnungen für die polymorphe Lichtdermatose sind PLD, PLE, Mallorca- Akne und eine Vielzahl von weiteren Bezeichnungen, wie sie in der Literatur (z. B. A. Voelckel et al. Zentralblatt Haut- und Geschlechtskrankheiten (1989), 156, S. 2), ange geben sind.Other terms for polymorphic photodermatosis include PLD, PLE, Mallorcan Acne and a variety of other names, as described in the literature (eg. Voelckel et al. Zentralblatt skin and venereal diseases (1989), 156, p. 2) give.
Hauptsächlich werden Antioxidantien als Schutzsubstanzen gegen den Verderb der sie enthaltenden Zubereitungen verwendet. Dennoch ist bekannt, daß auch in der menschli chen und tierischen Haut unerwünschte Oxidationsprozesse auftreten können.Mainly antioxidants are used as protective substances against the spoilage of them used preparations containing. Nevertheless, it is known that in menschli Skin and animal skin undesirable oxidation processes can occur.
Im Aufsatz "Skin Diseases Associated with Oxidative Injury" in "Oxidative Stress in Der matology", S. 323 ff. (Marcel Decker Inc., New York, Basel, Hong Kong, Herausgeber: Jürgen Fuchs, Frankfurt, und Lester Packer, Berkeley/Californien), werden oxidative Schäden der Haut und ihre näheren Ursachen aufgeführt.In the article "Skin Diseases Associated with Oxidative Injury" in "Oxidative Stress in the Matology, p. 323 et seq. (Marcel Decker Inc., New York, Basel, Hong Kong, publisher: Jürgen Fuchs, Frankfurt, and Lester Packer, Berkeley, California), become oxidative Damage to the skin and its nearer causes listed.
Auch aus dem Grunde, solchen Reaktionen vorzubeugen, können kosmetischen oder dermatologischen Formulierungen zusätzlich Antioxidantien und/oder Radikalfänger einverleibt werden.Also, to prevent such reactions, cosmetic or cosmetic dermatological formulations additionally antioxidants and / or radical scavengers be incorporated.
Zwar sind einige Antioxidantien und Radikalfänger bekannt. So ist bereits in den US-Pa tentschriften 4,144,325 und 4,248,861 sowie aus zahlreichen anderen Dokumenten vor geschlagen worden, Vitamin E, eine Substanz mit bekannter antioxidativer Wirkung in Lichtschutzformulierungen einzusetzen, dennoch bleibt auch hier die erzielte Wirkung weit hinter der erhofften zurück.Although some antioxidants and radical scavengers are known. So is already in the US Pa pending 4,144,325 and 4,248,861 and from numerous other documents been beaten, vitamin E, a substance with known antioxidant activity in Nevertheless, the effect achieved here also remains here far behind the hoped for.
Weitere Aufgabe der vorliegenden Erfindung war es daher, die Nachteile des Standes der Technik zu vermeiden und insbesondere die durch Umweltnoxen verursachten Schäden dauerhaft, nachhaltig und ohne das Risiko von Nebenwirkungen zu beheben bzw. ihnen vorzubeugen.Another object of the present invention was therefore to overcome the disadvantages of the prior art to avoid the technology and in particular those caused by environmental noxae Damage permanently, sustainably and without the risk of side effects remedy or to prevent them.
Es hat sich überraschenderweise herausgestellt, daß die
Verwendung von Substanzen gewählt aus der Gruppe:
Ipriflavon (7-Isopropoxy-Isoflavon), Formononetin (7-Hydroxy-4'-Methoxyiso
flavon), Ononin (Formononetin-7-O-β-D-Glucopyranosid), 4'-Isopropyl-Isofla
von, Mono-hydroxy-Isoflavone, Mono-hydroxy-Dihydro-Isoflavone, Mono
hydroxy-Tetrahydro-Isoflavone, O-Desmethylangolensin, Dihydro-Daidzein (Di
hydro-7,4'-Dihydroxy-Isoflavon), Tetrahydro-Daidzein (Tetrahydro-7,4'-Di
hydroxy-Isoflavon), Dihydro-Genistein (Dihydro-5,7,4'-Trihydroxy-Isoflavon), 2-
Dehydro-O-Desmethyl-Angolensin, Dehydroequol, 4-Hydroxy-7-Glucose-
Isoflavon und 5-Hydroy-7,4'-Dimethoxy-Isoflavon
in kosmetischen oder dermatologischen Zubereitungen zur Behandlung, Pflege und
Prophylaxe von sensibler Haut und/oder zur Behandlung und Prophylaxe der Symp
tome einer negativen Veränderung der physiologischen Homeostase der gesunden
Haut.
den Nachteilen das Standes der Technik abhilft.It has surprisingly been found that the use of substances selected from the group:
Ipriflavone (7-isopropoxy-isoflavone), formononetin (7-hydroxy-4'-methoxyisoflavone), ononine (formononetin-7-O-.beta.-D-glucopyranoside), 4'-isopropyl-isoflavone, mono-hydroxy-isoflavones , Mono-hydroxy-dihydro-isoflavones, mono-hydroxy-tetrahydro-isoflavones, O-desmethylangolensin, dihydro-daidzein (dihydro-7,4'-dihydroxy-isoflavone), tetrahydro-daidzein (tetrahydro-7,4'-dihydroxy Isoflavone), dihydro-genistein (dihydro-5,7,4'-trihydroxy-isoflavone), 2-dehydro-O-desmethyl-angolensin, dehydroequol, 4-hydroxy-7-glucose isoflavone and 5-hydroxy-7, 4'-dimethoxy-isoflavone
in cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and / or for the treatment and prophylaxis of the symptoms of a negative change in the physiological homeostasis of the healthy skin.
the disadvantages of the prior art helps.
Bevorzugt enthalten kosmetische oder dermatologische Zubereitungen gemäß der Erfin dung 0,001 bis 10 Gew.-%, besonders bevorzugt 0,01 bis 1 Gew.-%, an Isoflavonen, bezogen auf die Gesamtzusammensetzung der Zubereitungen.Cosmetic or dermatological preparations according to the invention preferably contain from 0.001 to 10% by weight, particularly preferably from 0.01 to 1% by weight, of isoflavones, based on the total composition of the preparations.
Bei Anwendung der erfindungsgemäß verwendeten Wirkstoffe bzw. kosmetischer oder
topischer dermatologischer Zubereitungen mit einem wirksamen Gehalt an erfindungs
gemäß verwendeten Wirkstoffen ist in überraschender Weise eine wirksame Behand
lung, aber auch eine Prophylaxe von
When using the active ingredients used in the invention or cosmetic or topical dermatological preparations with an effective content of fiction, according to the active ingredients used in a surprising treatment is effective treatment, but also a prophylaxis of
- - Veränderungen der normalen Lipidperoxidation,- changes in normal lipid peroxidation,
- - defizitären, sensitiven oder hypoaktiven Hautzuständen oder defizitären, sensitiven oder hypoaktiven Zuständen von Hautanhangsgebilden,- deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive states of skin appendages,
- - entzündlichen Hautzuständen,- inflammatory skin conditions,
- - atopischem Ekzem, polymorpher Lichtdermatose, Psoriasis, Vitiligo- atopic eczema, polymorphic photodermatosis, psoriasis, vitiligo
- - empfindlicher, juckender oder gereizter Haut, - sensitive, itchy or irritated skin,
- - Veränderung des Ceramid-, Lipid- und Energiestoffwechsels der gesunden Haut,Changing the ceramide, lipid and energy metabolism of healthy skin,
- - Veränderung des physiologischen transepidermalen Wasserverlustes,Change in physiological transepidermal water loss,
- - Verminderung der Hauthydratation und Abnahme des Feuchtigkeitsgehaltes der Haut,Reduction of skin hydration and decrease of moisture content of Skin,
- - Veränderung des Natural Moisturizing Factor Gehaltes,- Change in Natural Moisturizing Factor content,
- - Verminderung der Zell-Zell-Kommunikation,- reduction of cell-cell communication,
- - Mangelerscheinungen der intrazellulären DNS-Synthese,Deficiency symptoms of intracellular DNA synthesis,
- - DNS-Schädigungen und Verminderung von endogenen DNS-Reparaturmechanis men,DNA damage and reduction of endogenous DNA repair mechanism men,
- - Aktivierung von Metalloproteinasen und/oder anderer Proteasen bzw. Inhibierung der entsprechenden endogenen Inhibitoren dieser Enzyme,Activation of metalloproteinases and / or other proteases or inhibition the corresponding endogenous inhibitors of these enzymes,
- - Abweichungen von den normalen post-translationalen Modifikationen von Bindege websbestandteilen,- Deviations from the normal post-translational modifications of Bindege websbestandteilen,
- - Veränderungen des normalen Hyaluronsäure- und Glycosaminoglycangehaltes der gesunden Haut,Changes in the normal hyaluronic acid and glycosaminoglycans content of healthy skin,
- - Schuppenbildung der Haare,- dandruff of the hair,
- - Hautbrüchigkeit und Hautermüdung,- skin brittleness and skin fatigue,
- - Erhöhung der normalen Keratinozytenproliferation,Increase in normal keratinocyte proliferation,
- - Verminderung der natürlichen Regeneration und Struktur der Haare,- reduction of natural regeneration and structure of hair,
- - umweltbedingten (durch Rauchen, Smog, reaktive Sauerstoffspezies, freie Radikale verursachten) negativen Veränderungen der Haut und der Hautanhangsgebilde- environmental (through smoking, smog, reactive oxygen species, free radicals caused) negative changes of the skin and the skin appendages
möglich.possible.
Es ist erfindungsgemäß insbesondere äußerst vorteilhaft, den erfindungsgemäß ver wendeten Wirkstoff bzw. kosmetische oder topische dermatologische Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwendetem Wirkstoff zur kosmetischen oder dermatologischen Behandlung oder Prophylaxe unerwünschter Hautzustände zu verwenden.It is particularly advantageous according to the invention, ver according to the invention used active substance or cosmetic or topical dermatological preparations an effective content of the active ingredient used according to the invention for the cosmetic or dermatological treatment or prophylaxis of undesirable skin conditions use.
Erfindungsgemäß können Zubereitungen, welche die erfindungsgemäßen Wirkstoffkom binationen enthalten, übliche Antioxidantien eingesetzt werden.According to the invention, preparations containing the active compound com contain common antioxidants.
Vorteilhaft werden die Antioxidantien gewählt aus der Gruppe bestehend aus Aminosäu ren (z. B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z. B. Urocaninsäure) und deren Derivate, Peptide wie D,L-Carnosin, D-Carnosin, L-Carnosin und deren Derivate (z. B. Anserin), Carotinoide, Carotine (z. B. α-Carotin, β-Carotin, Lycopin) und deren Derivate, Liponsäure und deren Derivate (z. B. Dihydroliponsäure), Aurothio glucose, Propylthiouracil und andere Thiole (z. B. Thioredoxin, Glutathion, Cystein, Cystin, Cystamin und deren Glycosyl-, N-Acetyl-, Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyl-, Cholesteryl- und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearylthiodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulf oximinverbindungen (z. B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsul fone, Penta-, Hexa-, Heptathioninsulfoximin) in sehr geringen verträglichen Dosierungen (z. B. pmol bis µmol/kg), ferner (Metall)-Chelatoren (z. B. α-Hydroxyfettsäuren, Palmitin säure, Phytinsäure, Lactoferrin), α-Hydroxysäuren (z. B. Citronensäure, Milchsäure, Ap felsäure), Huminsäure, Gallensäure, Gallenextrakte, Bilirubin, Biliverdin, EDTA, EGTA und deren Derivate, ungesättigte Fettsäuren und deren Derivate (z. B. γ-Linolensäure, Linolsäure, Ölsäure), Folsäure und deren Derivate, Alanindiessigsäure, Flavonoide, Po lyphenole, Catechine, Vitamin C und Derivate (z. B. Ascorbylpalmitat, Mg-Ascor bylphosphat, Ascorbylacetat), Tocopherole und Derivate (z. B. Vitamin-E-acetat), sowie Koniferylbenzoat des Benzoeharzes, Rutinsäure und deren Derivate, Ferulasäure und deren Derivate, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihydroguajaretsäure, Trihydroxybutyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Zink und dessen Derivate (z. B. ZnO, ZnSO4) Selen und dessen Derivate (z. B. Selenmethionin), Stilbene und deren Derivate (z. B. Stilbenoxid, Trans-Stilbenoxid) und die erfindungsgemäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe.Advantageously, the antioxidants are selected from the group consisting of amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and derivatives thereof, peptides such as D, L-carnosine, D Carnosine, L-carnosine and their derivatives (eg anserine), carotenoids, carotenes (eg α-carotene, β-carotene, lycopene) and their derivatives, lipoic acid and derivatives thereof (eg dihydrolipoic acid) , Aurothio glucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, Palmitoyl, oleyl, γ-linoleyl, cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and derivatives thereof (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (e.g. Buthionine sulfoximines, Homocysteinsulfoximin, Buthioninsul fone, penta-, hexa-, heptathionine sulfoximine) in very low tolerated dosages (eg. Pmol to μmol / kg), furthermore (metal) chelators (for example α-hydroxyfatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (for example citric acid, lactic acid, rocker acid), humic acid, Bile acids, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, alaninediacetic acid, flavonoids, polyphenols, catechins, vitamin C and derivatives (e.g., ascorbyl palmitate, Mg-ascorbyl phosphate, ascorbyl acetate), tocopherols and derivatives (e.g., vitamin E acetate), and benzoic acid coniferyl benzoate, rutinic acid and derivatives thereof, ferulic acid and its derivatives, butylhydroxytoluene, butylated hydroxyanisole , Nordihydroguaiacetic acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO 4 ) selenium and its derivatives (eg selenomethionine), stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and the derivatives suitable for this purpose (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active substances mentioned.
Die Menge der Antioxidantien (eine oder mehrere Verbindungen) in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05 bis 20 Gew.-%, insbesondere 1 bis 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung.The amount of antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30 wt .-%, particularly preferably 0.05 to 20 wt .-%, in particular 1 to 10 wt .-%, based on the total weight of the preparation.
Ferner kann es von Vorteil sein, die erfindungsgemäßen Wirkstoffe zu verkapseln, z. B. als sogenannte solid lipid nanoparts mit Hilfe von aufgeschmolzenen Wachsen, die un ter anderem, aber nicht ausschließlich, gewählt sein können aus der Gruppe der Ester wachse, Triglyceridwachse oder Kohlenwasserstoffwachse. Weiterhin kann es von Vorteil sein die erfindungsgemäßen Wirkstoffe in Polymere zu verkapseln, z. B. in Parti kel auf Basis hochvernetzter Polymethacrylate und/oder Cellulosetriacetate und/oder als Core/Shell-Partikel mit einer Hülle aus Poly(oxymethylurea), Nylon, Polyamide, Poly urethan, Polyester, Gelatine und Polyolefine.Furthermore, it may be advantageous to encapsulate the active compounds according to the invention, for. B. as so-called solid lipid nanoparts with the help of melted waxes, the un Others, but not exclusively, may be selected from the group of esters waxes, triglyceride waxes or hydrocarbon waxes. Furthermore it can by Be advantageous to encapsulate the active compounds of the invention in polymers, eg. B. in Parti based on highly crosslinked polymethacrylates and / or cellulose triacetates and / or as Core / shell particles with a shell of poly (oxymethylurea), nylon, polyamides, poly urethane, polyester, gelatin and polyolefins.
Die Prophylaxe bzw. die kosmetische oder dermatologische Behandlung mit dem erfin dungsgemäß verwendeten Wirkstoff bzw. mit den kosmetischen oder topischen derma tologischen Zubereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwende tem Wirkstoff erfolgt in der üblichen Weise, und zwar dergestalt, daß der erfindungsge mäß verwendete Wirkstoff bzw. die kosmetischen oder topischen dermatologischen Zu bereitungen mit einem wirksamen Gehalt an erfindungsgemäß verwendetem Wirkstoff auf die betroffenen Hautstellen aufgetragen wird.The prophylaxis or the cosmetic or dermatological treatment with the inventions used according to the active ingredient or with the cosmetic or topical derma use tological preparations with an effective content of the invention Active ingredient is carried out in the usual way, in such a way that the erfindungsge the active ingredient used or the cosmetic or topical dermatological additives preparations with an effective content of active ingredient used in the invention is applied to the affected skin areas.
Vorteilhaft kann der erfindungsgemäß verwendete Wirkstoff eingearbeitet werden in üb liche kosmetische und dermatologische Zubereitungen, welche in verschiedenen For men vorliegen können. So können sie z. B. eine Lösung, eine Emulsion vom Typ Was ser-in-Öl (W/O) oder vom Typ Öl-in-Wasser (O/W), oder eine multiple Emulsionen, bei spielsweise vom Typ Wasser-in-Öl-in-Wasser (W/O/W) oder Öl-in-Wasser-in-Öl (O/W/O), eine Hydrodispersion oder Lipodispersion, ein Gel, eine Pickering-Emulsion, einen festen Stift oder auch ein Aerosol darstellen.Advantageously, the active ingredient used in the invention can be incorporated in üb Liche cosmetic and dermatological preparations, which in various For may be present. So they can z. As a solution, an emulsion of the type What ser-in-oil (W / O) or oil-in-water (O / W), or multiple emulsions For example, the type of water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a Pickering emulsion, represent a solid pin or an aerosol.
Erfindungsgemäße Emulsionen im Sinne der vorliegenden Erfindung, z. B. in Form einer Creme, einer Lotion, einer kosmetischen Milch sind vorteilhaft und enthalten z. B. Fette, Öle, Wachse und/oder andere Fettkörper, sowie Wasser und einen oder mehrere Emul gatoren, wie sie üblicherweise für einen solchen Typ der Formulierung verwendet wer den.According to the invention emulsions, z. B. in the form of a Cream, a lotion, a cosmetic milk are advantageous and contain z. Fats, Oils, waxes and / or other fatty substances, as well as water and one or more emul gators, as commonly used for such a type of formulation the.
Es ist auch möglich und vorteilhaft im Sinne der vorliegenden Erfindung, den erfin dungsgemäß verwendeten Wirkstoff in wäßrige Systeme bzw. Tensidzubereitungen zur Reinigung der Haut und der Haare einzufügen.It is also possible and advantageous within the meaning of the present invention, the inventions used according to the invention in aqueous systems or surfactant preparations for To cleanse the skin and hair.
Es ist dem Fachmann natürlich bekannt, daß anspruchsvolle kosmetische Zusammen setzungen zumeist nicht ohne die üblichen Hilfs- und Zusatzstoffe denkbar sind. Dar unter zählen beispielsweise Konsistenzgeber, Füllstoffe, Parfüm, Farbstoffe, Emulgatoren, zusätzliche Wirkstoffe wie Vitamine oder Proteine, Lichtschutzmittel, Stabilisatoren, Insektenrepellentien, Alkohol, Wasser, Salze, antimikrobiell, proteolytisch oder keratoly tisch wirksame Substanzen usw.Of course, it is known to those skilled in the art that sophisticated cosmetic compositions usually not without the usual auxiliaries and additives are conceivable. Dar include, for example, bodying agents, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, light stabilizers, stabilizers, Insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratoly table effective substances etc.
Mutatis mutandis gelten entsprechende Anforderungen an die Formulierung medizini scher Zubereitungen.Mutatis mutandis, corresponding requirements apply to the formulation medical shear preparations.
Medizinische topische Zusammensetzungen im Sinne der vorliegenden Erfindung ent halten in der Regel ein oder mehrere Medikamente in wirksamer Konzentration. Der Einfachheit halber wird zur sauberen Unterscheidung zwischen kosmetischer und medi zinischer Anwendung und entsprechenden Produkten auf die gesetzlichen Bestimmun gen der Bundesrepublik Deutschland verwiesen (z. B. Kosmetikverordnung, Lebens mittel- und Arzneimittelgesetz).Medical topical compositions according to the present invention ent usually keep one or more drugs in effective concentration. The For the sake of simplicity, a clear distinction between cosmetic and medi application and corresponding products to the legal requirements referred to in the Federal Republic of Germany (eg Cosmetics Regulation, Lebens Central and Drug Law).
Es ist dabei ebenfalls von Vorteil, den erfindungsgemäß verwendeten Wirkstoff als Zu satzstoff zu Zubereitungen zu geben, die bereits andere Wirkstoffe für andere Zwecke enthalten.It is also advantageous to use the active ingredient according to the invention as to give preparations which already have other active substances for other purposes contain.
Entsprechend können kosmetische oder topische dermatologische Zusammensetzun gen im Sinne der vorliegenden Erfindung, je nach ihrem Aufbau, beispielsweise ver wendet werden als Hautschutzcrème, Reinigungsmilch, Sonnenschutzlotion, Nähr creme, Tages- oder Nachtcreme usw. Es ist gegebenenfalls möglich und vorteilhaft, die erfindungsgemäßen Zusammensetzungen als Grundlage für pharmazeutische Formu lierungen zu verwenden.Accordingly, cosmetic or topical dermatological compositions according to the present invention, depending on their structure, for example ver to be used as a skin protection cream, cleansing milk, sunscreen lotion, nutrient Cream, day or night cream, etc. It may be possible and advantageous to the Compositions of the invention as a basis for pharmaceutical Formu lierungen to use.
Es ist auch vorteilhaft im Sinne der vorliegenden Erfindung, kosmetische und dermatolo gische Zubereitungen zu erstellen, deren hauptsächlicher Zweck nicht der Schutz vor Sonnenlicht ist, die aber dennoch einen Gehalt an UV-Schutzsubstanzen enthalten. So werden z. B. in Tagescremes oder Makeup-Produkten gewöhnlich UV-A- bzw. UV-B-Fil tersubstanzen eingearbeitet. Auch stellen UV-Schutzsubstanzen, ebenso wie Antioxi dantien und, gewünschtenfalls, Konservierungsstoffe, einen wirksamen Schutz der Zu bereitungen selbst gegen Verderb dar. Günstig sind ferner kosmetische und dermatolo gische Zubereitungen, die in der Form eines Sonnenschutzmittels vorliegen. It is also advantageous in the context of the present invention, cosmetic and dermatolo to prepare gische preparations whose main purpose is not to protect against Sunlight is, but still contain a content of UV-protective substances. So be z. As in day creams or makeup products usually UV-A or UV-B-Fil tersubstanzen incorporated. Also, UV protectants, as well as antioxidants dants and, if desired, preservatives, effective protection of Preparations themselves against spoilage are also favorable cosmetic and dermatolo gische preparations, which are in the form of a sunscreen.
Dementsprechend enthalten die Zubereitungen im Sinne der vorliegenden Erfindung vorzugsweise neben einem oder mehreren erfindungsgemäß verwendeten Wirkstoffen zusätzlich mindestens eine weitere UV-A- und/oder UV-B-Filtersubstanz. Die Formulie rungen können, obgleich nicht notwendig, gegebenenfalls auch ein oder mehrere orga nische und/oder anorganische Pigmente als UV-Filtersubstanzen enthalten, welche in der Wasser- und/oder der Ölphase vorliegen können.Accordingly, the preparations according to the present invention contain preferably in addition to one or more active ingredients used in the invention additionally at least one further UV-A and / or UV-B filter substance. The formula although not necessary, may also include one or more orga contain nische and / or inorganic pigments as UV filter substances, which in the water and / or the oil phase may be present.
Bevorzugte anorganische Pigmente sind Metalloxide und/oder andere in Wasser schwerlösliche oder unlösliche Metallverbindungen, insbesondere Oxide des Titans (TiO2), Zinks (ZnO), Eisens (z. B. Fe2O3), Zirkoniums (ZrO2), Siliciums (SiO2), Mangans (z. B. MnO), Aluminiums (Al2O3), Cers (z. B. Ce2O3), Mischoxide der entsprechenden Metalle sowie Abmischungen aus solchen Oxiden.Preferred inorganic pigments are metal oxides and / or other water-insoluble or insoluble metal compounds, in particular oxides of titanium (TiO 2 ), zinc (ZnO), iron (eg Fe 2 O 3 ), zirconium (ZrO 2 ), silicon ( SiO 2 ), manganese (for example MnO), aluminum (Al 2 O 3 ), cerium (for example Ce 2 O 3 ), mixed oxides of the corresponding metals and mixtures of such oxides.
Solche Pigmente können im Sinne der vorliegenden Erfindung vorteilhaft oberflächlich behandelt ("gecoatet") sein, wobei beispielsweise ein amphiphiler oder hydrophober Charakter gebildet werden bzw. erhalten bleiben soll. Diese Oberflächenbehandlung kann darin bestehen, daß die Pigmente nach an sich bekannten Verfahren mit einer dünnen hydrophoben Schicht versehen werden.Such pigments may advantageously be superficial in the sense of the present invention be treated ("coated"), wherein, for example, an amphiphilic or hydrophobic Character should be formed or preserved. This surface treatment may consist in that the pigments according to known methods with a thin hydrophobic layer can be provided.
Erfindungsgemäß vorteilhaft sind z. B. Titandioxidpigmente, die mit Octylsilanol be schichtet sind. Geeignete Titandioxidpartikel sind unter der Handelsbezeichnung T805 bei der Firma Degussa erhältlich. Besonders vorteilhaft sind ferner mit Aluminiumstearat beschichtete TiO2-Pigmente, z. B. die unter der Handelsbezeichnung MT 100 T bei der Firma TAYCA erhältlichen.According to the invention are advantageous z. As titanium dioxide pigments which are coated with octylsilanol be. Suitable titanium dioxide particles are available under the trade name T805 from Degussa. Also particularly advantageous are aluminum stearate coated with TiO 2 pigments, z. As those available under the trade name MT 100 T from TAYCA.
Eine weitere vorteilhafte Beschichtung der anorganische Pigmente besteht aus Dime thylpolysiloxan (auch: Dimethicon), einem Gemisch vollmethylierter, linearer Siloxanpoly mere, die endständig mit Trimethylsiloxy-Einheiten blockiert sind. Besonders vorteilhaft im Sinne der vorliegenden Erfindung sind Zinkoxid-Pigmente, die auf diese Weise be schichtet werden.Another advantageous coating of the inorganic pigments consists of dime thylpolysiloxane (also: dimethicone), a mixture of fully methylated, linear siloxane poly monomers which are terminally blocked with trimethylsiloxy units. Especially advantageous For the purposes of the present invention are zinc oxide pigments, be in this way be be layered.
Vorteilhaft ist ferner eine Beschichtung der anorganischen Pigmente mit einem Gemisch aus Dimethylpolysiloxan, insbesondere Dimethylpolysiloxan mit einer durchschnittlichen Kettenlänge von 200 bis 350 Dimethylsiloxan-Einheiten, und Silicagel, welches auch als Simethicone bezeichnet wird. Es ist insbesondere von Vorteil, wenn die anorganischen Pigmente zusätzlich mit Aluminiumhydroxid bzw. Aluminiumoxidhydrat (auch: Alumina, CAS-Nr.: 1333-84-2) beschichtet sind. Besonders vorteilhaft sind Titandioxide, die mit Simethicone und Alumina beschichtet sind, wobei die Beschichtung auch Wasser ent halten kann. Ein Beispiel hierfür ist das unter dem Handelsnamen Eusolex T2000 bei der Firma Merck erhältliche Titandioxid.Furthermore, a coating of the inorganic pigments with a mixture is advantageous of dimethylpolysiloxane, in particular dimethylpolysiloxane with an average Chain length of 200 to 350 dimethylsiloxane units, and silica gel, which is also known as Simethicone is called. It is particularly advantageous if the inorganic Pigments additionally with aluminum hydroxide or alumina hydrate (also: alumina, CAS No .: 1333-84-2). Titanium dioxides which are particularly advantageous are Simethicone and alumina are coated, the coating also ent can hold. An example of this is the under the trade name Eusolex T2000 at The company Merck available titanium dioxide.
Vorteilhaftes organisches Pigment im Sinne der vorliegenden Erfindung ist das 2,2'-Me thylen-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol) [INCI: Bisoctyl triazol], welches unter der Handelsbezeichnung Tinosorb® M bei der CIBA-Chemikalien GmbH erhältlich ist.Advantageous organic pigment in the context of the present invention is the 2,2'-Me thylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol) [INCI: bisoctyl triazole], which is marketed under the trade name Tinosorb® M in CIBA chemicals GmbH is available.
Vorteilhaft enthalten erfindungsgemäße Zubereitungen Substanzen, die UV-Strahlung im UV-A- und/oder UV-B-Bereich absorbieren, wobei die Gesamtmenge der Filtersub stanzen z. B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 20 Gew.-%, insbesonde re 1,0 bis 15,0 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die das Haar bzw. die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen. Sie können auch als Son nenschutzmittel fürs Haar oder die Haut dienen.Advantageously, preparations according to the invention contain substances which are UV radiation absorb in the UV-A and / or UV-B range, the total amount of the filtersub punching z. B. 0.1 wt .-% to 30 wt .-%, preferably 0.5 to 20 wt .-%, insbesonde 1.0 to 15.0% by weight, based on the total weight of the preparations, of to provide cosmetic preparations which pre-coat the hair or the skin protect the entire range of ultraviolet radiation. You can also as Son protect the hair or skin.
Vorteilhafte UV-A-Filtersubstanzen im Sinne der vorliegenden Erfindung sind Dibenzoyl methanderivate, insbesondere das 4-(tert.-Butyl)-4'-methoxydibenzoylmethan (CAS-Nr. 70356-09-1), welches von Givaudan unter der Marke Parsol® 1789 und von Merck unter der Handelsbezeichnung Eusolex® 9020 verkauft wird.Advantageous UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS no. 70356-09-1), which was sold by Givaudan under the trademark Parsol® 1789 and Merck under the trade name Eusolex® 9020 is sold.
Weitere vorteilhafte UV-A-Filtersubstanzen sind die Phenylen-1,4-bis-(2-benzimidazyl)- 3,3'-5,5'-tetrasulfonsäure und ihre Salze, besonders die entsprechenden Natrium-, Kali um- oder Triethanolammonium-Salze, insbesondere das Phenylen-1,4-bis-(2-benzimi dazyl)-3,3'-5,5'-tetrasulfonsäure-bis-natriumsalz mit der INCI-Bezeichnung Bisimidazy late, welches beispielsweise unter der Handelsbezeichnung Neo Heliopan AP bei Haarmann & Reimer erhältlich ist.Further advantageous UV-A filter substances are the phenylene-1,4-bis (2-benzimidazyl) - 3,3'-5,5'-tetrasulfonic acid and its salts, especially the corresponding sodium, potassium or triethanolammonium salts, in particular the phenylene-1,4-bis (2-benzimi dazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI name Bisimidazy late, which, for example, under the trade name Neo Heliopan AP at Haarmann & Reimer is available.
Ferner vorteilhaft sind das 1,4-di(2-oxo-10-Sulfo-3-bornylidenmethyl)-Benzol und dessen Salze (besonders die entprechenden 10-Sulfato-verbindungen, insbesondere das entsprechende Natrium-, Kalium- oder Triethanolammonium-Salz), das auch als Benzol- 1,4-di(2-oxo-3-bornylidenmethyl-10-sulfonsäure) bezeichnet wird.Also advantageous are 1,4-di (2-oxo-10-sulfo-3-bomylidenemethyl) benzene and its Salts (especially the entprechenden 10-sulfato compounds, in particular the corresponding Sodium, potassium or triethanolammonium salt), which is also known as benzene 1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid).
Vorteilhafte UV-Filtersubstanzen im Sinne der vorliegenden Erfindung sind ferner soge nannte Breitbandfilter, d. h. Filtersubstanzen, die sowohl UV-A- als auch UV-B-Strahlung absorbieren.Advantageous UV filter substances in the context of the present invention are also soge called broadband filter, d. H. Filter substances containing both UV-A and UV-B radiation absorb.
Vorteilhafte Breitbandfilter oder UV-B-Filtersubstanzen sind beispielsweise Bis-Resorci nyltriazinderivate. Insbesondere bevorzugt sind das 2,4-Bis-{[4-(2-Ethyl-hexyloxy)-2-hy droxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin (INCI: Aniso Triazin), welches unter der Handelsbezeichnung Tinosorb® S bei der CIBA-Chemikalien GmbH erhältlich ist.Advantageous broadband filters or UV-B filter substances are, for example, bis-resorci nyltriazinderivate. Particularly preferred are the 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hy droxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: aniso triazine), which is available under the Trade name Tinosorb® S is available from CIBA-Chemikalien GmbH.
Besonders vorteilhafte Zubereitungen im Sinne der vorliegenden Erfindung, die sich durch einen hohen bzw. sehr hohen UV-A-Schutz auszeichnen, enthalten bevorzugt mehrere UV-A- und/oder Breitbandfilter, insbesondere Dibenzoylmethanderivate [bei spielsweise das 4-(tert.-Butyl)-4'-methoxydibenzoylmethan], Benzotriazolderivate [bei spielsweise das 2,2'-Methylen-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)- phenol)], Phenylen-1,4-bis-(2-benzimidazyl)-3,3'-5,5'-tetrasulfonsäure und/oder ihre Salze, das 1,4-di(2-oxo-10-Sulfo-3-bomylidenmethyl)-Benzol und/oder dessen Salze und/oder das 2,4-Bis-{[4-(2-Ethyl-hexyloxy)-2-hydroxy]-phenyl}6-(4-methoxyphenyl)- 1,3,5-triazin, jeweils einzeln oder in beliebigen Kombinationen miteinander.Particularly advantageous preparations in the context of the present invention, which characterized by a high or very high UV-A protection, preferably contain several UV-A and / or broadband filters, in particular Dibenzoylmethanderivate [in For example, the 4- (tert-butyl) -4'-methoxydibenzoylmethan], benzotriazole derivatives [at For example, the 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) - phenol)], phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and / or their Salts, the 1,4-di (2-oxo-10-sulfo-3-bomylidenmethyl) benzene and / or its salts and / or the 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} 6- (4-methoxyphenyl) - 1,3,5-triazine, each individually or in any combination with each other.
Auch andere UV-Filtersubstanzen, welche das Strukturmotiv
Other UV filter substances, which are the structural motif
aufweisen, sind vorteilhafte UV-Filtersubstanzen im Sinne der vorliegenden Erfindung,
beispielsweise die in der Europäischen Offenlegungsschrift EP 570 838 A1 beschriebe
nen s-Triazinderivate, deren chemische Struktur durch die generische Formel
are advantageous UV filter substances in the context of the present invention, for example, those described in European Published Patent Application EP 570 838 A1 nen s-triazine derivatives, their chemical structure by the generic formula
wiedergegeben wird, wobei
R einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cycloalkyl
rest, gegebenenfalls substituiert mit einer oder mehreren C1-C4-Alkylgruppen, dar
stellt,
X ein Sauerstoffatom oder eine NH-Gruppe darstellt,
R1 einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cycloalkyl
rest, gegebenenfalls substituiert mit einer oder mehreren C1-C4- Alkylgruppen,
oder ein Wasserstoffatom, ein Alkalimetallatom, eine Ammoniumgruppe oder eine
Gruppe der Formel
is reproduced, wherein
R is a branched or unbranched C 1 -C 18 -alkyl radical, a C 5 -C 12 -cycloalkyl radical, optionally substituted by one or more C 1 -C 4 -alkyl groups,
X represents an oxygen atom or an NH group,
R 1 is a branched or unbranched C 1 -C 18 -alkyl radical, a C 5 -C 12 -cycloalkyl radical, optionally substituted by one or more C 1 -C 4 -alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group the formula
bedeutet, in welcher
A einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cyclo
alkyl- oder Arylrest darstellt, gegebenenfalls substituiert mit einer oder meh
reren C1-C4-Alkylgruppen,
R3 ein Wasserstoffatom oder eine Methylgruppe darstellt,
n eine Zahl von 1 bis 10 darstellt,
R2 einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cycloalkyl
rest, gegebenenfalls substituiert mit einer oder mehreren C1-C4-Alkylgruppen, dar
stellt, wenn X die NH-Gruppe darstellt, und
einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cycloalkyl
rest, gegebenenfalls substituiert mit einer oder mehreren C1-C4-Alkylgruppen,
oder ein Wasserstoffatom, ein Alkalimetallatom, eine Ammoniumgruppe oder eine
Gruppe der Formel
means in which
A is a branched or unbranched C 1 -C 18 -alkyl radical, a C 5 -C 12 -cycloalkyl or aryl radical, optionally substituted by one or more C 1 -C 4 -alkyl groups,
R 3 represents a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
R 2 represents a branched or unbranched C 1 -C 18 alkyl radical, a C 5 -C 12 cycloalkyl radical optionally substituted by one or more C 1 -C 4 alkyl groups, when X represents the NH group, and
a branched or unbranched C 1 -C 18 -alkyl radical, a C 5 -C 12 -cycloalkyl radical, optionally substituted by one or more C 1 -C 4 -alkyl groups, or a hydrogen atom, an alkali metal atom, an ammonium group or a group of the formula
bedeutet, in welcher
A einen verzweigten oder unverzweigten C1-C18-Alkylrest, einen C5-C12-Cyclo
alkyl- oder Arylrest darstellt, gegebenenfalls substituiert mit einer oder meh
reren C1-C4-Alkylgruppen,
R3 ein Wasserstoffatom oder eine Methylgruppe darstellt,
n eine Zahl von 1 bis 10 darstellt,
wenn X ein Sauerstoffatom darstellt.means in which
A is a branched or unbranched C 1 -C 18 -alkyl radical, a C 5 -C 12 -cycloalkyl or aryl radical, optionally substituted by one or more C 1 -C 4 -alkyl groups,
R 3 represents a hydrogen atom or a methyl group,
n represents a number from 1 to 10,
when X represents an oxygen atom.
Besonders bevorzugte UV-Filtersubstanz im Sinne der vorliegenden Erfindung ist ferner
ein unsymmetrisch substituiertes s-Triazin, dessen chemische Struktur durch die Formel
Particularly preferred UV filter substance in the context of the present invention is also an unsymmetrically substituted s-triazine whose chemical structure is represented by the formula
wiedergegeben wird, welches im Folgenden auch als Dioctylbutylamidotriazon (INCI: Dioctylbutamidotriazone) bezeichnet wird und unter der Handelsbezeichnung UVA- SORB HEB bei Sigma 3 V erhältlich ist.which is also referred to below as dioctylbutylamidotriazone (INCI: Dioctylbutamidotriazone) and is sold under the trade name UVA- SORB HEB is available from Sigma 3V.
Vorteilhaft im Sinne der vorliegenden Erfindung ist auch ein symmetrisch substituiertes s-Triazin, das 4,4',4"-(1,3,5-Triazin-2,4,6-triyltriimino)-tris-benzoesäure-tris(2-ethylhexyl ester), synonym: 2,4,6-Tris-[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazin (INCI: Octyl Triazone), welches von der BASF Aktiengesellschaft unter der Warenbezeichnung UVINUL® T 150 vertrieben wird.Advantageous in the context of the present invention is also a symmetrically substituted s-triazine containing 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2-ethylhexyl ester), synonymous: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: Octyl Triazone), which is marketed by BASF Aktiengesellschaft under the trade name UVINUL® T 150 is sold.
Auch in der Europäischen Offenlegungsschrift 775 698 werden bevorzugt einzusetzen
de Bis-Resorcinyltriazinderivate beschrieben, deren chemische Struktur durch die gene
rische Formel
Also in the European Patent Application 775,698 de preferred to use de bis-Resorcinyltriazinderivate described their chemical structure by the gene genetic formula
wiedergegeben wird, wobei R1, R2 und A1 verschiedenste organische Reste repräsen tieren.is reproduced, wherein R 1 , R 2 and A 1 represent a wide variety of organic radicals animals.
Vorteilhaft im Sinne der vorliegenden Erfindung sind ferner das 2,4-Bis-{[4-(3-sulfonato)- 2-hydroxy-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin Natriumsalz, das 2,4-Bis-{[4-(3-(2-Propyloxy)-2-hydroxy-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxy phenyl)-1,3,5-triazin, das 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl)-6-[4-(2-meth oxyethyl-carboxyl)-phenylamino]-1,3,5-triazin, das 2,4-Bis-{[4-(3-(2-propyloxy)-2-hy droxy-propyloxy)-2-hydroxy]-phenyl}-6-[4-(2-ethyl-carboxyl)-phenylamino]-1,3,5-triazin, das 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(1-methyl-pyrrol-2-yl)-1,3,5-tri azin, das 2,4-Bis-{[4-tris(trimethylsiloxy-silylpropyloxy)-2-hydroxy]-phenyl}-6-(4-methoxy phenyl)-1,3,5-triazin, das 2,4-Bis-{[4-(2"-methylpropenyloxy)-2-hydroxy-phenyl}-6-(4-me thoxyphenyl)-1,3,5-triazin und das 2,4-Bis-{[4-(1',1',1',3',5',5',5'-Heptamethylsiloxy-2"- methyl-propyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin.Advantageous in the context of the present invention are also the 2,4-bis - {[4- (3-sulfonato) - 2-hydroxy-propyloxy) -2-hydroxy] -phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine sodium salt, the 2,4-bis - {[4- (3- (2-propyloxy) -2-hydroxy-propyloxy) -2-hydroxy] -phenyl} -6- (4-methoxy phenyl) -1,3,5-triazine which is 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl) -6- [4- (2-meth oxyethyl-carboxyl) -phenylamino] -1,3,5-triazine which is 2,4-bis - {[4- (3- (2-propyloxy) -2-hy droxy-propyloxy) -2-hydroxy] phenyl} -6- [4- (2-ethyl-carboxyl) -phenylamino] -1,3,5-triazine, 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl} -6- (1-methylpyrrol-2-yl) -1,3,5-tri azine, the 2,4-bis - {[4-tris (trimethylsiloxy-silylpropyloxy) -2-hydroxy] -phenyl} -6- (4-methoxy phenyl) -1,3,5-triazine which is 2,4-bis - {[4- (2 "-methylpropenyloxy) -2-hydroxy-phenyl} -6- (4-me thoxyphenyl) -1,3,5-triazine and the 2,4-bis - {[4- (1 ', 1', 1 ', 3', 5 ', 5', 5'-heptamethylsiloxy-2 "- methyl-propyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine.
Ein vorteilhafter Breitbandfilter im Sinne der vorliegenden Erfindung ist das 2,2'-Methy len-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)-phenol), welches unter der Handelsbezeichnung Tinosorb® M bei der CIBA-Chemikalien GmbH erhältlich ist.An advantageous broadband filter in the context of the present invention is the 2,2'-methyl lenbis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol), which is available under the Trade name Tinosorb® M is available from CIBA-Chemikalien GmbH.
Vorteilhafter Breitbandfilter im Sinne der vorliegenden Erfindung ist ferner das 2-(2H- benzotriazol-2-yl)-4-methyl-6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]di siloxanyl]propyl]-phenol (CAS-Nr.: 155633-54-8) mit der INCI-Bezeichnung Drometrizole Trisiloxane.Advantageous broadband filter according to the present invention, the 2- (2H- benzotriazol-2-yl) -4-methyl-6- [2-methyl-3- [1,3,3,3-tetramethyl-1 - [(trimethylsilyl) oxy] di siloxanyl] propyl] phenol (CAS No .: 155633-54-8) with the INCI name Drometrizole Trisiloxane.
Die UV-B- und/oder Breitband-Filter können öllöslich oder wasserlöslich sein. Vorteil
hafte öllösliche UV-B- und/oder Breitband-Filtersubstanzen sind z. B.:
The UV-B and / or broadband filters may be oil-soluble or water-soluble. Advantage is oil-soluble UV-B and / or broadband filter substances are z. B .:
- - 3-Benzylidencampher-Derivate, vorzugsweise 3-(4-Methylbenzyliden)campher, 3- Benzylidencampher;3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3 benzylidenecamphor;
- - 4-Aminobenzoesäure-Derivate, vorzugsweise 4-(Dimethylamino)-benzoesäure(2- ethylhexyl)ester, 4-(Dimethylamino)benzoesäureamylester;4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2- ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
- - 2,4,6-Trianilino-(p-carbo-2'-ethyl-1'-hexyloxy)-1,3,5-triazin;- 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine;
- - Ester der Benzalmalonsäure, vorzugsweise 4-Methoxybenzalmalonsäuredi(2-ethyl hexyl)ester; Esters of benzalmalonic acid, preferably 4-methoxybenzalmalonic acid di (2-ethyl hexyl ester);
- - Ester der Zimtsäure, vorzugsweise 4-Methoxyzimtsäure(2-ethylhexyl)ester, 4-Meth oxyzimtsäureisopentylester;Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-meth oxyzimtsäureisopentylester;
- - Derivate des Benzophenons, vorzugsweise 2-Hydroxy-4-methoxybenzophenon, 2- Hydroxy-4-methoxy-4'-methylbenzophenon, 2,2'-Dihydroxy-4-methoxybenzophenonDerivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2- Hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone
- - sowie an Polymere gebundene UV-Filter.- As well as bound to polymers UV filters.
Vorteilhafte wasserlösliche UV-B- und/oder Breitband-Filtersubstanzen sind z. B.:
Advantageous water-soluble UV-B and / or broadband filter substances are z. B .:
- - Salze der 2-Phenylbenzimidazol-5-sulfonsäure, wie ihr Natrium-, Kalium- oder ihr Tri ethanolammonium-Salz, sowie die Sulfonsäure selbst;Salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or tri ethanolammonium salt, as well as the sulfonic acid itself;
- - Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z. B. 4-(2-Oxo-3-bornyliden methyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und deren Salze.- Sulfonic acid derivatives of 3-Benzylidencamphers, such as. B. 4- (2-oxo-3-bomylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidenemethyl) sulfonic acid and their salts.
Eine weiterere erfindungsgemäß vorteilhaft zu verwendende Lichtschutzfiltersubstanz ist das Ethylhexyl-2-cyano-3,3-diphenylacrylat (Octocrylen), welches von BASF unter der Bezeichnung Uvinul® N 539 erhältlich ist.A further light stabilizer filter substance to be advantageously used according to the invention is ethylhexyl 2-cyano-3,3-diphenylacrylate (octocrylene), available from BASF under the Designation Uvinul® N 539 is available.
Es kann auch von erheblichem Vorteil sein, polymergebundene oder polymere UV-Filter substanzen in Zubereitungen gemäß der vorliegenden Erfindung zu verwenden, insbe sondere solche, wie sie in der WO-A-92/20690 beschrieben werden.It can also be of considerable advantage, polymer-bound or polymeric UV filters to use substances in preparations according to the present invention, esp especially those as described in WO-A-92/20690.
Ferner kann es gegebenenfalls von Vorteil sein, erfindungsgemäß weitere UV-A- und/oder UV-B-Filter in kosmetische oder dermatologische Zubereitungen einzuarbei ten, beispielsweise bestimmte Salicylsäurederivate wie 4-Isopropylbenzylsalicylat, 2- Ethylhexylsalicylat (= Octylsalicylat), Homomenthylsalicylat.Furthermore, it may be advantageous, according to the invention, to obtain further UVA and / or UV-B filter incorporated into cosmetic or dermatological preparations example, certain salicylic acid derivatives such as 4-Isopropylbenzylsalicylat, 2- Ethyl hexyl salicylate (= octyl salicylate), homomenthyl salicylate.
Die Liste der genannten UV-Filter, die im Sinne der vorliegenden Erfindung eingesetzt werden können, soll selbstverständlich nicht limitierend sein.The list of said UV filters used in the context of the present invention of course, should not be limiting.
Vorteilhaft enthalten die erfindungsgemäßen Zubereitungen die Substanzen, die UV- Strahlung im UV-A- und/oder UV-B-Bereich absorbieren, in einer Gesamtmenge von z. B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 20 Gew.-%, insbesondere 1,0 bis 15,0 Gew.-%, jeweils bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische Zubereitungen zur Verfügung zu stellen, die das Haar bzw. die Haut vor dem ge samten Bereich der ultravioletten Strahlung schützen. Sie können auch als Sonnen schutzmittel fürs Haar oder die Haut dienen.The preparations according to the invention advantageously contain the substances which Absorb radiation in the UV-A and / or UV-B range, in a total of z. 0.1% to 30% by weight, preferably 0.5 to 20% by weight, especially 1.0 to 15.0% by weight, in each case based on the total weight of the preparations, of cosmetic To provide preparations that the hair or skin before ge protect the entire area of ultraviolet radiation. They can also be called suns protect the hair or skin.
Die erfindungsgemäßen kosmetischen und dermatologischen Zubereitungen können kosmetische Wirk-, Hilfs- und/oder Zusatzstoffe enthalten, wie sie üblicherweise in sol chen Zubereitungen verwendet werden, z. B. Antioxidationsmittel, Konservierungsmittel, Bakterizide, Parfüme, Substanzen zum Verhindern des Schäumens, Farbstoffe, Pig mente, die färbende Wirkung haben, Verdickungsmittel, oberflächenaktive Substanzen, Emulgatoren, weichmachende, anfeuchtende und/oder feuchthaltende Substanzen, Fet te, Öle, Wachse oder andere übliche Bestandteile einer kosmetischen oder dermato logischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elek trolyte, organische Lösungsmittel oder Silikonderivate.The cosmetic and dermatological preparations according to the invention can contain cosmetic active ingredients, auxiliaries and / or additives, as commonly used in sol chen preparations are used, for. Anti-oxidants, preservatives, Bactericides, perfumes, anti-foaming agents, dyes, Pig pigments which have a coloring effect, thickeners, surface-active substances, Emulsifiers, softening, moisturizing and / or moisturizing substances, Fet te, oils, waxes or other common ingredients of a cosmetic or dermato logical formulation such as alcohols, polyols, polymers, foam stabilizers, elec trolytes, organic solvents or silicone derivatives.
Sofern die kosmetische oder dermatologische Zubereitung im Sinne der vorliegenden
Erfindung eine Lösung oder Emulsion oder Dispersion darstellt, können als Lösungsmit
tel verwendet werden:
If the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, it is possible to use as solvents:
- - Wasser oder wäßrige Lösungen- water or aqueous solutions
- - Öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizi nusöl;- Oils, such as triglycerides of capric or caprylic acid, but preferably Rizi nusöl;
- - Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z. B. mit Isopropanol, Propy lenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C- Zahl oder mit Fettsäuren;- Fats, waxes and other natural and synthetic fats, preferably Esters of fatty acids with lower C-number alcohols, e.g. B. with isopropanol, propy glycol or glycerol, or esters of fatty alcohols with lower alkanoic acids. Number or with fatty acids;
- - Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmono ethyl- oder -monobutylether, Propylenglykolmonomethyl, -monoethyl- oder -mono butylether, Diethylenglykolmonomethyl- oder -monoethylether und analoge Pro dukte.- Alcohols, diols or polyols low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol mono ethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or mono butyl ether, diethylene glycol monomethyl or monoethyl ether and analogous Pro -products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein.In particular, mixtures of the abovementioned solvents are used. For alcoholic solvents, water can be another ingredient.
Die Ölphase der Emulsionen, Oleogele bzw. Hydrodispersionen oder Lipodispersionen im Sinne der vorliegenden Erfindung wird vorteilhaft gewählt aus der Gruppe der Ester aus gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkancar bonsäuren einer Kettenlänge von 3 bis 30 C-Atomen und gesättigten und/oder ungesät tigten, verzweigten und/oder unverzweigten Alkoholen einer Kettenlänge von 3 bis 30 C- Atomen, aus der Gruppe der Ester aus aromatischen Carbonsäuren und gesättigten und/oder ungesättigten, verzweigten und/oder unverzweigten Alkoholen einer Ketten länge von 3 bis 30 C-Atomen. Solche Esteröle können dann vorteilhaft gewählt werden aus der Gruppe Isopropylmyristat, Isopropylpalmitat, Isopropylstearat, Isopropyloleat, n- Butylstearat, n-Hexyllaurat, n-Decyloleat, Isooctylstearat, Isononylstearat, Isononyliso nonanoat, 2-Ethylhexylpalmitat, 2-Ethylhexyllaurat, 2-Hexyldecylstearat, 2-Octyldodecyl palmitat, Oleyloleat, Oleylerucat, Erucyloleat, Erucylerucat sowie synthetische, halbsyn thetische und natürliche Gemische solcher Ester, z. B. Jojobaöl.The oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions For the purposes of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched Alkancar bonsäuren a chain length of 3 to 30 carbon atoms and saturated and / or unsatd saturated, branched and / or unbranched alcohols of a chain length of 3 to 30 C Atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols of a chain length of 3 to 30 carbon atoms. Such ester oils can then be chosen advantageously from the group isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n- Butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl iso nonanoate, 2-ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, and synthetic, semysin thetic and natural mixtures of such esters, e.g. B. jojoba oil.
Ferner kann die Ölphase vorteilhaft gewählt werden aus der Gruppe der verzweigten und unverzweigten Kohlenwasserstoffe und -wachse, der Silkonöle, der Dialkylether, der Gruppe der gesättigten oder ungesättigten, verzweigten oder unverzweigten Alkoho le, sowie der Fettsäuretriglyceride, namentlich der Triglycerinester gesättigter und/oder ungesättigter, verzweigter und/oder unverzweigter Alkancarbonsäuren einer Kettenlän ge von 8 bis 24, insbesondere 12-18 C-Atomen. Die Fettsäuretriglyceride können bei spielsweise vorteilhaft gewählt werden aus der Gruppe der synthetischen, halbsyntheti schen und natürlichen Öle, z. B. Olivenöl, Sonnenblumenöl, Sojaöl, Erdnußöl, Rapsöl, Mandelöl, Palmöl, Kokosöl, Palmkernöl und dergleichen mehr.Furthermore, the oil phase can be advantageously selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols le, as well as the fatty acid triglycerides, namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids of a chain length ge from 8 to 24, in particular 12-18 C-atoms. The fatty acid triglycerides may be included For example, be advantageously selected from the group of synthetic, semisyntheti and natural oils, eg. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, Almond oil, palm oil, coconut oil, palm kernel oil, and the like.
Auch beliebige Abmischungen solcher Öl- und Wachskomponenten sind vorteilhaft im Sinne der vorliegenden Erfindung einzusetzen. Es kann auch gegebenenfalls vorteilhaft sein, Wachse, beispielsweise Cetylpalmitat, als alleinige Lipidkomponente der Ölphase einzusetzen.Any mixtures of such oil and wax components are advantageous in Use of the present invention. It may also be advantageous if necessary waxes, for example cetyl palmitate, as the sole lipid component of the oil phase use.
Vorteilhaft wird die Ölphase gewählt aus der Gruppe 2-Ethylhexylisostearat, Octyldo decanol, Isotridecylisononanoat, Isoeicosan, 2-Ethylhexylcocoat, C12-15-Alkylbenzoat, Capryl-Caprinsäure-triglycerid, Dicaprylylether.Advantageously, the oil phase is selected from the group consisting of 2-ethylhexyl isostearate, octyldodanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C 12-15 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
Besonders vorteilhaft sind Mischungen aus C12-15-Alkybenzoat und 2-Ethylhexylisostea rat, Mischungen aus C12-15-Alkybenzoat und Isotridecylisononanoat sowie Mischungen aus C12-15-Alkybenzoat, 2-Ethylhexylisostearat und Isotridecylisononanoat.Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-Ethylhexylisostea rat, mixtures of C 12-15 -alkyl benzoate and Isotridecylisononanoat and mixtures of C 12-15 -alkyl benzoate, 2-Ethylhexylisostearat and Isotridecylisononanoat.
Von den Kohlenwasserstoffen sind Paraffinöl, Squalan und Squalen vorteilhaft im Sinne der vorliegenden Erfindung zu verwenden.Of the hydrocarbons, paraffin oil, squalane and squalene are advantageous in the sense to use the present invention.
Vorteilhaft kann die Ölphase ferner einen Gehalt an cyclischen oder linearen Silikonölen aufweisen oder vollständig aus solchen Ölen bestehen, wobei allerdings bevorzugt wird, außer dem Silikonöl oder den Silikonölen einen zusätzlichen Gehalt an anderen Ölpha senkomponenten zu verwenden.Advantageously, the oil phase may further contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred that in addition to the silicone oil or the silicone oils an additional content of other oil phase vertical components to use.
Vorteilhaft wird Cyclomethicon (Octamethylcyclotetrasiloxan) als erfindungsgemäß zu verwendendes Silikonöl eingesetzt. Aber auch andere Silikonöle sind vorteilhaft im Sin ne der vorliegenden Erfindung zu verwenden, beispielsweise Hexamethylcyclotrisiloxan, Polydimethylsiloxan, Poly(methylphenylsiloxan).Advantageously, cyclomethicone (octamethylcyclotetrasiloxane) is used as the invention used silicone oil. But other silicone oils are beneficial in Sin ne of the present invention, for example hexamethylcyclotrisiloxane, Polydimethylsiloxane, poly (methylphenylsiloxane).
Besonders vorteilhaft sind ferner Mischungen aus Cyclomethicon und Isotridecylisono nanoat, aus Cyclomethicon und 2-Ethylhexylisostearat.Also particularly advantageous are mixtures of cyclomethicone and isotridecylisono nanoate, from cyclomethicone and 2-ethylhexyl isostearate.
Die wäßrige Phase der erfindungsgemäßen Zubereitungen enthält gegebenenfalls vor teilhaft Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmonoethyl- oder -monobutylether, Propylenglykolmonomethyl, -monoethyl- oder -monobutylether, Diethylenglykolmonomethyl- oder -monoethylether und analoge Produkte, ferner Alko hole niedriger C-Zahl, z. B. Ethanol, Isopropanol, 1,2-Propandiol, Glycerin sowie insbe sondere ein oder mehrere Verdickungsmittel, welches oder welche vorteilhaft gewählt werden können aus der Gruppe Siliciumdioxid, Aluminiumsilikate, Polysaccharide bzw. deren Derivate, z. B. Hyaluronsäure, Xanthangummi, Hydroxypropylmethylcellulose, be sonders vorteilhaft aus der Gruppe der Polyacrylate, bevorzugt ein Polyacrylat aus der Gruppe der sogenannten Carbopole, beispielsweise Carbopole der Typen 980, 981, 1382, 2984, 5984, jeweils einzeln oder in Kombination.The aqueous phase of the preparations according to the invention optionally contains partly alcohols, diols or polyols low C number, and their ethers, preferably Ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, Diethylene glycol monomethyl or monoethyl ether and analogous products, further Alko get low C-number, z. As ethanol, isopropanol, 1,2-propanediol, glycerol and in particular in particular one or more thickening agents, which or which are advantageously chosen can be selected from the group silicon dioxide, aluminum silicates, polysaccharides or their derivatives, eg. Hyaluronic acid, xanthan gum, hydroxypropylmethylcellulose, be particularly advantageous from the group of polyacrylates, preferably a polyacrylate from the Group of so-called Carbopols, for example Carbopols of types 980, 981, 1382, 2984, 5984, each alone or in combination.
Erfindungsgemäß verwendete Gele enthalten üblicherweise Alkohole niedriger C-Zahl, z. B. Ethanol, Isopropanol, 1,2-Propandiol, Glycerin und Wasser bzw. ein vorstehend genanntes Öl in Gegenwart eines Verdickungsmittels, das bei ölig-alkoholischen Gelen vorzugsweise Siliciumdioxid oder ein Aluminiumsilikat, bei wäßrig-alkoholischen oder al koholischen Gelen vorzugweise ein Polyacrylat ist.Gels used according to the invention usually contain alcohols of low C number, z. For example, ethanol, isopropanol, 1,2-propanediol, glycerol and water or an above called oil in the presence of a thickening agent, the oily-alcoholic gels preferably silicon dioxide or an aluminum silicate, with aqueous-alcoholic or al koholischen gels is preferably a polyacrylate.
Feste Stifte enthalten z. B. natürliche oder synthetische Wachse, Fettalkohole oder Fettsäureester.Fixed pins contain z. As natural or synthetic waxes, fatty alcohols or Fatty acid ester.
Übliche Grundstoffe, welche für die Verwendung als kosmetische Stifte im Sinne der vorliegenden Erfindung geeignet sind, sind flüssige Öle (z. B. Paraffinöle, Ricinusöl, Iso propylmyristat), halbfeste Bestandteile (z. B. Vaseline, Lanolin), feste Bestandteile (z. B. Bienenwachs, Ceresin und Mikrokristalline Wachse bzw. Ozokerit) sowie hochschmel zende Wachse (z. B. Carnaubawachs, Candelillawachs)Usual raw materials which are suitable for use as cosmetic sticks in the sense of are suitable in the present invention, liquid oils (eg., Paraffin oils, castor oil, Iso propyl myristate), semi-solid ingredients (e.g., vaseline, lanolin), solid ingredients (e.g. Beeswax, ceresin and microcrystalline waxes or ozokerite) and Hochschmel shiny waxes (eg carnauba wax, candelilla wax)
Als Treibmittel für aus Aerosolbehältern versprühbare kosmetische und/oder dermato logische Zubereitungen im Sinne der vorliegenden Erfindung sind die üblichen bekann ten leichtflüchtigen, verflüssigten Treibmittel, beispielsweise Kohlenwasserstoffe (Pro pan, Butan, Isobutan) geeignet, die allein oder in Mischung miteinander eingesetzt wer den können. Auch Druckluft ist vorteilhaft zu verwenden.As a propellant for sprayable from aerosol containers cosmetic and / or dermato Logical preparations in the sense of the present invention are the usual ones highly volatile, liquefied propellants, for example hydrocarbons (Pro pan, butane, isobutane) which are used alone or mixed with one another you can. Also, compressed air is advantageous to use.
Natürlich weiß der Fachmann, daß es an sich nichttoxische Treibgase gibt, die grund sätzlich für die Verwirklichung der vorliegenden Erfindung in Form von Aerosolpräpa raten geeignet wären, auf die aber dennoch wegen bedenklicher Wirkung auf die Um welt oder sonstiger Begleitumstände verzichtet werden sollte, insbesondere Fluorkoh lenwasserstoffe und Fluorchlorkohlenwasserstoffe (FCKW).Of course, the expert knows that there are nontoxic propellants per se, the reason in addition to the realization of the present invention in the form of Aerosolpräpa would be appropriate, but nevertheless due to a dubious effect on the order world or other accompanying circumstances should be waived, in particular Fluorkoh hydrocarbons and chlorofluorocarbons (CFCs).
Kosmetische Zubereitungen im Sinne der vorliegenden Erfindung können auch als Gele vorliegen, die neben einem wirksamen Gehalt am erfindungsgemäßen Wirkstoff und da für üblicherweise verwendeten Lösungsmitteln, bevorzugt Wasser, noch organische Verdickungsmittel, z. B. Gummiarabikum, Xanthangummi, Natriumalginat, Cellulose-De rivate, vorzugsweise Methylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose oder anorganische Verdickungs mittel, z. B. Aluminiumsilikate wie beispielsweise Bentonite, oder ein Gemisch aus Poly ethylenglykol und Polyethylenglykolstearat oder -distearat, enthalten. Das Verdickungs mittel ist in dem Gel z. B. in einer Menge zwischen 0,1 und 30 Gew.-%, bevorzugt zwi schen 0,5 und 15 Gew.-%, enthalten. Cosmetic preparations according to the present invention may also be used as gels present, in addition to an effective content of the active ingredient according to the invention and there for commonly used solvents, preferably water, still organic Thickener, z. Gum arabic, xanthan gum, sodium alginate, cellulose de preferably, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, Hydroxypropylcellulose, hydroxypropylmethylcellulose or inorganic thickening medium, z. As aluminum silicates such as bentonites, or a mixture of poly ethylene glycol and polyethylene glycol stearate or distearate. The thickening is medium in the gel z. B. in an amount between 0.1 and 30 wt .-%, preferably zwi 0.5 and 15 wt .-%, contained.
Es ist insbesondere vorteilhaft im Sinne der vorliegenden Erfindung, wenn die erfin dungsgemäßen kosmetischen oder dermatologischen Zubereitungen weitere Wirkstoffe enthalten, insbesondere natürliche Wirkstoffe und/oder deren Derivate, wie z. B. alpha- Liponsäure, Phytoen, D-Biotin, Coenzym Q10, alpha Glucosylrutin, Carnitin, Carnosin, Osmolyte, Klee-Extrakt, Hopfen- bzw. Hopfen-Malz-Extrakt.It is particularly advantageous in the context of the present invention, when the inventions According to the cosmetic or dermatological preparations according to the invention further active ingredients contain, in particular natural agents and / or derivatives thereof, such as. Eg alpha- Lipoic acid, phytoene, D-biotin, coenzyme Q10, alpha glucosylrutin, carnitine, carnosine, Osmolyte, clover extract, hop or hop malt extract.
Der Gehalt dieser Wirkstoffe (eine oder mehrere Verbindungen) wird vorteilhaft aus dem Bereich von 0,0001 bis 30 Gew.-% gewählt, bezogen auf das Gesamtgewicht der Zube reitungen.The content of these active ingredients (one or more compounds) is advantageously from the Range from 0.0001 to 30 wt .-% selected, based on the total weight of Zube TION.
Die nachfolgenden Beispiele sollen die vorliegende Erfindung verdeutlichen, wobei un
ter "Isoflavone" hier im Speziellen eine oder mehrere der folgenden Substanzen zu ver
stehen ist:
Ipriflavon (7-Isopropoxy-Isoflavon), Formononetin (7-Hydroxy-4'-Methoxyisoflavon),
Ononin (Formononetin-7-O-β-D-Glucopyranosid), 4'-Isopropyl-Isoflavon, Mono-hydroxy-
Isoflavone, Mono-hydroxy-Dihydro-Isoflavone, Mono-hydroxy-Tetrahydro-Isoflavone, O-
Desmethylangolensin, Dihydro-Daidzein (Dihydro-7,4-Dihydroxy-Isoflavon), Tetrahydro-
Daidzein (Tetrahydro-7,4'-Dihydroxy-Isoflavon), Dihydro-Genistein (Dihydro-5,7,4'-Tri
hydroxy-Isoflavon), 2-Dehydro-O-Desmethyl-Angolensin, Dehydroequol, 4-Hydroxy-7-
Glucose-Isoflavon und 5-Hydroy-7,4'-Dimethoxy-Isoflavon
The following examples are intended to illustrate the present invention, wherein one or more of the following substances are to be understood here in particular as "isoflavones":
Ipriflavone (7-isopropoxy-isoflavone), formononetin (7-hydroxy-4'-methoxyisoflavone), ononine (formononetin-7-O-β-D-glucopyranoside), 4'-isopropyl-isoflavone, mono-hydroxy-isoflavones, mono -hydroxy-dihydro-isoflavones, mono-hydroxy-tetrahydro-isoflavones, O-desmethylangolensin, dihydro-daidzein (dihydro-7,4-dihydroxy-isoflavone), tetrahydro-daidzein (tetrahydro-7,4'-dihydroxy-isoflavone), Dihydro-genistein (dihydro-5,7,4'-trihydroxy-isoflavone), 2-dehydro-O-desmethyl-angolensin, dehydroequol, 4-hydroxy-7-glucose isoflavone and 5-hydroxy-7,4'- dimethoxy-isoflavone
Claims (5)
Ipriflavon (7-Isopropoxy-Isoflavon), Formononetin (7-Hydroxy-4'-Methoxy isoflavon), Ononin (Formononetin-7-O-β-D-Glucopyranosid), 4'-Isopropyl- Isoflavon, Mono-hydroxy-Isoflavone, Mono-hydroxy-Dihydro-Isoflavone, Mono-hydroxy-Tetrahydro-Isoflavone, O-Desmethylangolensin, Dihydro- Daidzein (Dihydro-7,4'-Dihydroxy-Isoflavon), Tetrahydro-Daidzein (Tetra hydro-7,4'-Dihydroxy-Isoflavon), Dihydro-Genistein (Dihydro-5,7,4'-Tri hydroxy-Isoflavon), 2-Dehydro-O-Desmethyl-Angolensin, Dehydroequol, 4- Hydroxy-7-Glucose-Isoflavon und 5-Hydroy-7,4'-Dimethoxy-Isoflavon
in kosmetischen oder dermatologischen Zubereitungen zur Behandlung, Pflege und Prophylaxe von sensibler Haut und/oder zur Behandlung und Prophylaxe der Symptome einer negativen Veränderung der physiologischen Homeostase der ge sunden Haut.1. Use of substances selected from the group:
Ipriflavone (7-isopropoxy-isoflavone), formononetin (7-hydroxy-4'-methoxyisoflavone), ononine (formononetin-7-O-β-D-glucopyranoside), 4'-isopropyl-isoflavone, mono-hydroxy-isoflavones, Mono-hydroxy-dihydro-isoflavones, mono-hydroxy-tetrahydro-isoflavones, O-desmethylangolensin, dihydro-daidzein (dihydro-7,4'-dihydroxy-isoflavone), tetrahydro-daidzein (tetra-hydro-7,4'-dihydroxy) Isoflavone), dihydro-genistein (dihydro-5,7,4'-trihydroxy-isoflavone), 2-dehydro-O-desmethyl-angolensin, dehydroequol, 4-hydroxy-7-glucose isoflavone and 5-hydroy-7, 4'-dimethoxy-isoflavone
in cosmetic or dermatological preparations for the treatment, care and prophylaxis of sensitive skin and / or for the treatment and prophylaxis of the symptoms of a negative change in the physiological homeostasis of the healthy skin.
Veränderungen der normalen Lipidperoxidation,
defizitäre, sensitive oder hypoaktive Hautzustände oder defizitäre, sensitive oder hypoaktive Zustände von Hautanhangsgebilden,
entzündliche Hautzuständen,
atopisches Ekzem, polymorphe Lichtdermatose, Psoriasis, Vitiligo,
empfindliche, juckende oder gereizte Haut,
Veränderung des Ceramid-, Lipid- und Energiestoffwechsels der gesunden Haut,
Veränderung des physiologischen transepidermalen Wasserverlustes,
Verminderung der Hauthydratation und Abnahme des Feuchtigkeitsgehaltes der Haut,
Veränderung des Natural Moisturizing Factor Gehaltes,
Verminderung der Zell-Zell-Kommunikation,
Mangelerscheinungen der intrazellulären DNS-Synthese,
DNS-Schädigungen und Verminderung von endogenen DNS-Reparaturmechanismen,
Aktivierung von Metalloproteinasen und/oder anderer Proteasen bzw. Inhibie rung der entsprechenden endogenen Inhibitoren dieser Enzyme,
Abweichungen von den normalen post-translationalen Modifikationen von Bin degewebsbestandteilen,
Veränderungen des normalen Hyaluronsäure- und Glycosaminoglycangehaltes der gesunden Haut,
Schuppenbildung der Haare,
Hautbrüchigkeit und Hautermüdung,
Erhöhung der normalen Keratinozytenproliferation,
Verminderung der natürlichen Regeneration der Haare,
umweltbedingte (durch Rauchen, Smog, reaktive Sauerstoffspezies, freie Radi kale oder dergleichen verursachte) negative Veränderungen der Haut und der Hautanhangsgebilde.2. Use according to claim 1, wherein the skin damage and / or negative Hautzu states one or more appearances from the following group:
Changes in normal lipid peroxidation,
deficient, sensitive or hypoactive skin conditions or deficient, sensitive or hypoactive states of skin appendages,
inflammatory skin conditions,
atopic eczema, polymorphic photodermatosis, psoriasis, vitiligo,
sensitive, itchy or irritated skin,
Change in the ceramide, lipid and energy metabolism of healthy skin,
Change in physiological transepidermal water loss,
Reduction of skin hydration and decrease of the moisture content of the skin,
Change in Natural Moisturizing Factor content,
Reduction of cell-cell communication,
Deficiency symptoms of intracellular DNA synthesis,
DNA damage and reduction of endogenous DNA repair mechanisms,
Activation of metalloproteinases and / or other proteases or inhibition of the corresponding endogenous inhibitors of these enzymes,
Deviations from the normal post-translational modifications of connective tissue components,
Changes in normal hyaluronic acid and glycosaminoglycan content of healthy skin,
Dandruff of the hair,
Skin brittleness and skin fatigue,
Increase in normal keratinocyte proliferation,
Reduction of natural regeneration of hair,
environmental (caused by smoking, smog, reactive oxygen species, free Rad kale or the like) negative changes in the skin and the skin appendages.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001122342 DE10122342A1 (en) | 2001-05-09 | 2001-05-09 | Use of isoflavones in cosmetic or dermatological preparations |
| PCT/EP2002/004624 WO2002089757A2 (en) | 2001-05-09 | 2002-04-26 | Use of isoflavones in cosmetic or dermatological preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001122342 DE10122342A1 (en) | 2001-05-09 | 2001-05-09 | Use of isoflavones in cosmetic or dermatological preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10122342A1 true DE10122342A1 (en) | 2002-11-14 |
Family
ID=7684041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2001122342 Withdrawn DE10122342A1 (en) | 2001-05-09 | 2001-05-09 | Use of isoflavones in cosmetic or dermatological preparations |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE10122342A1 (en) |
| WO (1) | WO2002089757A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10301631A1 (en) * | 2003-01-17 | 2004-07-29 | Beiersdorf Ag | Cosmetic and dermatological composition, useful e.g. for restructuring and rejuvenating skin, contains soya bean germ extract, vitamins C and E and alpha-glycosylrutin |
| KR20210062861A (en) * | 2019-11-22 | 2021-06-01 | 오산대학교 산학협력단 | Composition of whitening containing Ipriflavone as inhibitor of PKA, cosmetic composition and pharmaceutical composition containing the same, and manufacturing method for the same |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504409A (en) | 2002-07-24 | 2006-02-09 | チルドレンズ ホスピタル メディカル センター | Compositions and products containing enantiomeric equol and methods for their production |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| AU2002951271A0 (en) * | 2002-09-06 | 2002-09-19 | Novogen Research Pty Ltd | Repair of dna mutagenic damage |
| CZ2005181A3 (en) * | 2002-09-23 | 2005-08-17 | Novogen Research Pty Ltd | Skin photoageing and actinic damage treatment |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| AU2003286781B2 (en) | 2002-10-29 | 2009-05-21 | Brigham Young University | Use of equol for treating androgen mediated diseases |
| DE102004060314A1 (en) * | 2004-12-08 | 2006-08-31 | Beiersdorf Ag | Active ingredient combinations of one or more isoflavonoids and carnitine and / or one or more acyl-carnitines |
| CN108261376B (en) * | 2018-03-06 | 2021-01-12 | 上海科颜生物科技有限公司 | Three-dimensional moisturizing factor |
| CN109053667A (en) * | 2018-08-02 | 2018-12-21 | 山东大学 | A kind of separation method of isoflavone derivative and application |
| KR20200042284A (en) * | 2018-10-15 | 2020-04-23 | (주)아모레퍼시픽 | Composition for mineralocorticoid receptor activation inhibition |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056373A1 (en) * | 1997-06-11 | 1998-12-17 | Gorbach Sherwood L | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
| WO1999036050A1 (en) * | 1997-12-24 | 1999-07-22 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001213775A (en) * | 2000-02-03 | 2001-08-07 | Pola Chem Ind Inc | Stress mitigating preparation and skin care preparation including it |
-
2001
- 2001-05-09 DE DE2001122342 patent/DE10122342A1/en not_active Withdrawn
-
2002
- 2002-04-26 WO PCT/EP2002/004624 patent/WO2002089757A2/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056373A1 (en) * | 1997-06-11 | 1998-12-17 | Gorbach Sherwood L | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
| WO1999036050A1 (en) * | 1997-12-24 | 1999-07-22 | Novogen Research Pty. Ltd. | Compositions and method for protecting skin from uv induced immunosuppression and skin damage |
Non-Patent Citations (2)
| Title |
|---|
| 01042427 A * |
| JP Patent Abstracts of Japan: 10338633 A * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10301631A1 (en) * | 2003-01-17 | 2004-07-29 | Beiersdorf Ag | Cosmetic and dermatological composition, useful e.g. for restructuring and rejuvenating skin, contains soya bean germ extract, vitamins C and E and alpha-glycosylrutin |
| KR20210062861A (en) * | 2019-11-22 | 2021-06-01 | 오산대학교 산학협력단 | Composition of whitening containing Ipriflavone as inhibitor of PKA, cosmetic composition and pharmaceutical composition containing the same, and manufacturing method for the same |
| KR102264451B1 (en) | 2019-11-22 | 2021-06-14 | 오산대학교 산학협력단 | Composition of whitening containing Ipriflavone as inhibitor of PKA, cosmetic composition and pharmaceutical composition containing the same, and manufacturing method for the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002089757A2 (en) | 2002-11-14 |
| WO2002089757A3 (en) | 2003-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1127568B1 (en) | Cosmetic and dermatological light protective formulations containing benzotriazole derivatives and alkylnaphthalates | |
| EP1129696B1 (en) | Stabilization of oxidation- and/or UV- sensitive active agents | |
| DE10121375B4 (en) | Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin | |
| DE19933466A1 (en) | Antioxidants and/or radical scavenger for use in cosmetic or dermatological compositions, useful e.g. for preventing skin aging and inflammatory reactions | |
| DE10132953A1 (en) | Use of hops or Hop-malt extracts in cosmetic or dermatological preparations for the prophylaxis against and treatment of degenerative skin symptoms | |
| DE10048260A1 (en) | Cosmetic or dermatological composition for combating undesirable skin pigmentation, contains aminoguanidine or its derivatives | |
| DE10038713B4 (en) | Cosmetic and dermatological light protection formulations containing unsymmetrically substituted triazine derivatives and dialkyl adipates | |
| DE10122342A1 (en) | Use of isoflavones in cosmetic or dermatological preparations | |
| EP1311234A2 (en) | Substances for inducing and intensifying the tanning mechanisms of the skin | |
| EP0821946A2 (en) | Stable sunscreening compositions containing surface-active glucose derivatives and water-soluble UV-filters | |
| DE10141472A1 (en) | Stabilization of active substances that are sensitive to oxidation and / or UV | |
| EP0860164B1 (en) | Cosmetic and dermatological composition for sun protection containing triazine derivates and butylenglycol diesters | |
| EP0935959B1 (en) | Use of beeswax to increase the UVA protection factor of cosmetic or dermatologic sunscreens | |
| DE10120315A1 (en) | Use of clover extract in cosmetic or dermatological preparations for the prophylaxis and treatment of degenerative skin symptoms | |
| EP1180360B2 (en) | Cosmetic and dermatologic sunscreen compositions containing asymmetrically substituted triazine derivatives and dialkylcarbonates | |
| EP1539206A1 (en) | Cosmetic or dermatological preparations having a content of anti-freezing proteins and/or anti-freezing glycoproteins | |
| EP1311233B1 (en) | Substances for inducing and intensifying the tanning mechanisms of the skin and cosmetic or dermatological preparations which contain said substances | |
| EP1062943B1 (en) | Cosmetic or dermatologic sunscreen compositions containing boron nitride and UV filters having triazine groups | |
| EP1186288B1 (en) | Cosmetic and dermatologic sunscreen compositions containing asymmetrically substituted triazine derivatives and organosiloxanes | |
| DE10121092A1 (en) | Cosmetic or dermatological formulations containing sericoside and / or plant extracts containing the same | |
| EP0895775B1 (en) | Lightprotection compositions containing inorganic pigments which are coated on their surface with UV filter substances | |
| DE10131796A1 (en) | Cosmetic or dermatological preparations containing cardiolipin, useful e.g. for treatment, care and prophylaxis of sensitive skin and treatment of inflammatory conditions such as eczema or psoriasis | |
| EP1142552A2 (en) | Cosmetic and dermatological photoprotective compositions comprising unsymmetrically substituted triazine derivatives and propylene glycol dicaprylate dicaprate | |
| EP1166759A2 (en) | Use of lecithines to enhance the light protection factor and /or the UVA-protection of cosmetic or dermatologic light protection compositions | |
| DE19845266A1 (en) | Use of butylhydroxytoluene for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |